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ABSTRACT

Author: Puls, Theodore J. PhD
Institution: Purdue University
Degree Received: December 2017
Title: Engineering Novel 3D Tumor-stroma Models to Bridge the Gap Between Preclinical Drug
Development and Human Clinical Outcomes
Major Professor: Sherry Voytik-Harbin
While much progress has been made in the war on cancer, shortcomings in the drug
development process have kept anti-cancer clinical trial success rates low. One of the many
factors implicated in this is the lack of pathophysiologically relevant and predictive preclinical
models. Specifically, traditional preclinical tumor models do not capture tumor
microenvironment complexity and heterogeneity, while advanced three-dimensional (3D)
models suffer from poor reproducibility, lack of relevant and standardized extracellular matrix
(ECM), and inability to interface with automated, high-throughput systems. Because of this, it
has been suggested that developing novel phenotypic tumor models which balance the need for
complexity and relevance with the ability to scale-up and translate, may help reduce the high
attrition rates of clinical trials. Toward this end, this work describes the development and
validation of a novel preclinical tumor model striving to achieve this balance. Model
development was specifically focused on metastasis, as it remains the main cause of cancer
deaths and has few good preclinical models. Since one major shortcoming of 3D in-vitro models
is a lack of standardized, relevant ECM, initial work focused on defining the role of ECM
composition and biophysical properties in guiding invasive phenotypes. Using a customizable
and standardized oligomeric type I collagen, we demonstrated that 3D collagen fibril architecture
and model geometry were key determinants of phenotypic trends and important design
considerations for future model development. This work was followed by the design and
validation of a custom fabrication platform to enable the rapid, reproducible embedment of
tunable tumor-tissue spheres within a customizable 3D ECM. It was validated that this model
can distinguish various metastatic phenotypes, is compatible with low-passage, patient-derived
cells, and is able to interface with automated imaging systems. Overall, this work represents the
first steps of design, verification, and validation of a novel 3D metastasis model which can serve
as a relevant and predictive tool for high-throughput, high-content preclinical drug development.
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1. INTRODUCTION

Motivation
While much progress has been made in the war on cancer since President Nixon
“declared war” in 1971 by signing the National Cancer Act, victory in this war still remains
elusive. In 2016, in the US alone, nearly 600,000 people died from cancer and over 1.5 million
people were newly diagnosed with some form of the disease [1]. In addition to the immeasurable
emotional toll this takes, caring for cancer patients also costs more than $120 billion a year [2],
and the research and development costs of developing a single anticancer drug are estimated to
be over $1 billion [3]. While these numbers are quite staggering, a more astonishing figure, that
is less well known, is that the success rate of anticancer drugs going from a phase I trial to full
FDA approval has been estimated to be 13.4% [4]. In other words, nearly 90% of drugs that
show promise in preclinical testing fail when they are tested in humans. Additionally, 70% of
drugs fail during phase II trials, which is the first time the efficacy in humans is truly examined
[5]. Again, although some progress has been made in treating certain types of cancer and there
have been several breakthrough therapies, it is clear that there is still a vast amount of work that
needs to be done to make progress in the war on cancer.
As the above statistics suggest, one specific area that needs attention is the inefficient
drug development process. Clearly, a 90% failure rate in clinical trials suggests a lack of
predictive power in the preclinical phases of anticancer drug development. While this is a
multifaceted problem, two of the core issues lie in pharmaceutical companies’ drug development
strategy and in the preclinical models used to screen potential drugs [6–8]. Thus, it has been
suggested that shifting from a molecular target-based approach to a phenotypic screening
approach, as well as developing better preclinical models are two ways in which we can
potentially improve the abysmal success rate of anti-cancer drug development [9,10]. This
perspective serves as the primary motivation for the work of this thesis and is described in more
detail in the following sections.
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Drug Development Strategies and Preclinical Models
It is becoming apparent that traditional drug development strategies are not very efficient
or successful, and thus are in need of improvement [6,9]. Pharmaceutical companies, in general,
rely on two main drug development strategies, specifically molecular target-based screening and
phenotypic screening [9]. Molecular target-based screening, which has been industry standard
for nearly 30 years, involves an identified molecular target (e.g., signaling protein) and
associated biochemical screens focused on protein-protein interactions or enzyme activity. This
process is extremely time and resource intensive because, by definition, one must know the
mechanism of action of both the disease-related molecular target and the candidate drugs at the
forefront of development. Phenotypic screening, on the other hand, begins with developing a
disease model and associated assays focused on specific disease characteristics. One advantage
of this approach is that phenotypic models are more physiologically relevant than those used
early in target-based screening since they are cell- or tissue-based rather than protein- or enzymebased. Further, this method is attractive because it does not require complete mechanistic
understanding at the onset of development and is conducive to drug repurposing screens [9].
Additionally, between 1999 and 2008, the majority of newly approved drugs were developed
using phenotypic screening despite molecular-target based screening being far more widely used
in industry [7]. For these reasons, it has been suggested that increased use of phenotypic
screening may help reduce the high attrition rate of clinical trials [7,9,10].
Another main shortcoming of anticancer drug development lies in the preclinical models
used, which primarily consist of high-throughput two-dimensional (2D) cell culture and
subcutaneous xenograft mice [11]. 2D cell culture does not replicate critical features of the invivo tumor microenvironment, including extracellular matrix (ECM) interactions, tumor
heterogeneity, and stromal cell populations, and thus are not predictive of human tumor drug
sensitivity [12,13]. Preclinical animal models are used in an attempt to reduce the high false
positive rate of 2D models, however, it is questionable how much is really gained in terms of
predictive power from the most common in-vivo models—immunodeficient subcutaneous
xenograft mice. Expense, inefficiency, lack of relevant stroma, and species specific pathways are
a few shortcomings of these traditional murine models [14]. Further, 2D culture and xenograft
mice are oversimplified models of a very complex disease since they do not include relevant or
reproducible stromal interactions and are unable to measure some phenotypic outcomes [9].
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Since these traditional models do not accurately recreate important features of the tumor
microenvironment, the field of “tumor engineering” has arisen as researchers attempt to fill this
gap by developing novel three-dimensional (3D) cell culture models [15]. Current 3D tumor
models include tumor cells embedded within various 3D matrices, multi-cellular tumor
spheroids, and microfluidic models that work to incorporate numerous components of the tumor
microenvironment [12,15,16]. While these models do recapitulate certain aspects of human
tumors better than their 2D counterparts, there are still many shortcomings which hinder their
widespread adoption and preclinical application [17]. Reproducibility and lack of user control
are two of the most commonly problems for traditional naturally derived 3D culture materials
(e.g. Matrigel, monomeric type I collagen), as well as for tumor spheroids [18–21]. On the other
hand, complex microfluidic systems that incorporate stromal cells, vascular networks, and
dynamic perfusion are often limited in their 1) ability to provide quantifiable outcome measures
relevant to drug development or 2) capacity to be used for high-throughput screening [22,23].
Finally, while it is often assumed that advanced 3D models will be more predictive than 2D cell
culture this assumption is rarely validated for new developed models [22–24]. In summary,
while much progress has been made in 3D culture techniques, current 3D tumor models do not
provide readily translatable solutions that balances physiologic relevance needed for phenotypic
assays with ease of use and reproducibility required for high throughput screening [17].

Metastasis and Pancreatic Cancer
Since phenotypic screening appears to be an attractive strategy for making progress in the
war on cancer, and novel models of disease phenotypes are necessary for this strategy, the next
question that arises is: What phenotype should be the focus model development? Traditional
phenotypic screens usually target relatively simple phenotypes or cell behaviors such as survival
(live/dead) or relative metabolic activity, but clearly these types of assays can only go so far in
predicting a drug’s effect on a tumor. Since metastasis, the main cause of cancer deaths, has few
treatment options, it seems to be good candidate for the focus of new model development [25].
Metastasis is the process by which tumor cells invade into the surrounding tissue and spread
throughout the rest of the body. While all of the mechanisms at play in metastasis are not fully
elucidated, the general steps of this process include 1) epithelial to mesenchymal transition
(EMT) and invasion, 2) intravasation and dissemination, and 3) extravasation and colonization
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[26]. Because the metastatic process is not completely understood, molecular-target based
strategies, such as those targeting invasion and ECM degradation have been largely
disappointing [27,28]. Finally, there are few preclinical models that accurately recreate
metastatic phenotypes and can be used in high-throughput drug screens [25,29]. To this end, the
goal of this work is to develop a 3D in-vitro metastasis model which is focused on recreating the
initial steps of metastasis, EMT and invasion, while maintaining the ability to translate to highthroughput systems.
While the ultimate goal is to develop a model which can be customized and standardized
for many cancer types, for the sake of initial model development pancreatic cancer was
specifically chosen for this work. Pancreatic cancer, of which pancreatic ductal adenocarcinoma
(PDAC) is the most common type, is only the 12th most common cancer in the US, but it is the
3rd leading cause of cancer death with a 5-year survival rate of just 8.2% [30]. The reason for
this high mortality rate, is due to its late-stage diagnosis, difficulty of surgical intervention, and
high rates of drug resistance and metastasis [31]. The latter of these problems is thought to be
largely mediated by intense desmoplasia—another hallmark of pancreatic cancer. Desmoplasia is
characterized by over-active cancer-associated fibroblasts (CAFs) and increased deposition of
ECM components, especially type I collagen [32–34]. These features—the high rate of
metastasis and desmoplasia—will serve as the focal point for model development in this work.

Defining User Needs: The Ideal Preclinical Tumor Model
A recent perspective article from pharma-industry researchers provided a helpful “rule of
3” to aid in the development of predictive phenotypic models [10]. These authors suggest that
one must consider (1) the relevance of the model to the human disease of interest, (2) the
relevance of stimuli that yield the desired phenotype, and (3) the proximity of assay readouts to
clinical endpoints or outcomes. With regard to the first criteria, in-vitro models of solid tumors
must consider factors such as the source of tumor cells, inclusion of stromal cell populations,
ECM composition and biophysical properties, and culture format (geometry) [22,23,35]. For
PDAC specifically, since desmoplasia is such a prominent feature of this disease, including a
relevant type I collagen matrix and CAFs would be logical design criteria. Additionally, the
stimuli which recreates the invasive phenotype in these models should occur as naturally as
possible rather than being artificially induced, such as by genetic manipulation. Finally, the
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readouts of ideal metastasis models will be able to measure outcomes such as invasiveness,
metabolic activity and proliferation which would correlate to clinical outcomes of metastatic
spread, tumor dormancy, and tumor growth. Additional criteria for designing models which can
readily translate to the pharmaceutical industry include low-cost, rapid, reproducible, and simple
experimental set up, ability to interface with automated equipment (e.g. automated imaging
platforms, liquid handling robots), and validation of predictive power [22,23,36]. Taken together,
this can be summarized as a need to find a “balance between complexity and physiologic
relevance of culture method with its ease of use and potential for high throughput analyses [23].”

Note About Content and Organization of Thesis
Since this thesis is focused on model design and development, it has been framed with
regard to the medical device development process. The first part of this process is clearly
defining user needs and design requirements. The second stage of development is establishing a
set of design inputs followed by iterative design and testing to verify that the design outputs
match the design inputs. Finally, the capstone of the development process is validating that
user’s needs are met by the final design.. The above introductory material serves to define the
problem and needs that this thesis is addressing; much of the content here was drawn from my
Qualifying Literature Assessment (QLA) and Preliminary Exam document. Chapter 2 represents
a manuscript that is accepted for publication in PlosOne. This chapter details efforts to 1) define
how ECM composition and biophysical properties modulate EMT phenotype and 2) establish the
unique type I collagen formulation developed in the Harbin lab as a powerful tool for tumor
model development. Another key takeaway from Chapter 2 is that the collagen fibril architecture
and 3D model geometry are critical regulators of tumor invasive phenotypes and serve as
important design parameters for in-vitro tumor models. Chapter 3 represents a second manuscript
planned for submission that targets development, verification and progressive validation of a
high-throughput, high-content phenotypic model of PDAC metastasis. This chapter documents
that this model meets important user needs, including 1) rapid, reproducible experimental set up,
2) recapitulating various invasive phenotypes, and 3) the ability to interface with automated
imaging equipment. Finally, Chapter 4 outlines proposed next steps of model validation,
showcases some preliminary data for this validation work, and discusses overall conclusions and
perspectives from this thesis.
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2. 3D COLLAGEN FIBRILLAR MICROSTRUCTURE GUIDES
PANCREATIC CANCER CELL PHENOTYPE AND SERVES AS A
CRITICAL DESIGN PARAMETER FOR PHENOTYPIC MODELS OF
EMT

Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with an
estimated 5-year survival rate of around 5% [37]. PDAC is characterized by an intense stromal
reaction, known as desmoplasia, where overactive cancer associated fibroblasts deposit excessive
extracellular matrix (ECM), the bulk of which is fibrillar type I collagen [32,38]. It is widely
thought that this stromal remodeling and dysregulation of cell-ECM homeostasis serves to
promote cancer progression, including metastasis and drug resistance [38,39]. However, recent
evidence suggests that desmoplasia may paradoxically play an important protective role, where
resulting changes in ECM composition and architecture restrict rather than promote tumor
growth and invasion [40]. Clearly, tumor-stromal ECM interactions play a critical role in PDAC
pathophysiology; however, advanced in-vitro and in-vivo models are needed to achieve a more
complete mechanistic understanding [40–42]. This knowledge gap, which exists for not only
PDAC, but most solid tumors, precludes development of novel targeted therapies as well as
identification of better predictors of patient therapeutic response. Since patients generally die
from metastatic disease and PDAC has such a high metastasis rate, better understanding of how
stromal ECM guides tumor phenotype and behavior is paramount to improving clinical outcomes
[43–45].
ECM associated with PDAC, as well as normal tissues, is represented by two distinct
types, namely basement membrane (BM) and interstitial matrix (IM). BM, composed primarily
of laminin, non-fibrillar type IV collagen, and heparan sulfate proteoglycan, forms a thin sheetlike structure which supports and polarizes epithelial cell layers, separating them from the
underlying interstitial tissue compartment. In contrast, the predominant component of IM is
fibrillar type I collagen, within which individual mesenchymal cells (e.g., fibroblasts) reside. It is
noteworthy that a hallmark of tumor metastasis is epithelial to mesenchymal transition (EMT),
where epithelial cancer cells lose polarity and cell-cell associations while gaining a more
mesenchymal and invasive phenotype. Figure 2-1 highlights salient features of tumor EMT,
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Figure 2-1 Overview of EMT and associated tumor stromal ECM interactions.
Schematic shows key characteristics and progression of EMT, as epithelial cancer cells lose contact with
basement membrane and interface with the surrounding interstitial matrix which is composed primarily of
fibrillar type I collagen. Association with the stromal interstitial matrix correlates with transition from an
epithelial to a mesenchymal phenotype. HSPG = heparan sulfate proteoglycan.

drawing attention to the altered stromal ECM context encountered by tumor cells as they
increasingly interact with surrounding IM [44]. This marked difference in ECM context is often
overlooked in conventional EMT schematics where IM is often excluded and intracellular events
are emphasized [44,46].
Although it is evident that EMT is marked by dynamic tumor cell-ECM interactions,
where cells may engage both BM and IM components, many experimental in-vitro models lack
rigorous definition of relevant ECM molecular and physical properties [47,48]. In fact, tumor
EMT research has traditionally focused on soluble factor (e.g., TGF-1) induction and
intercellular signaling cascades [49,50]. However, since recent work suggest that matrix
composition and physical properties (e.g. microstructure and viscoelastic properties) are involved
in driving EMT, ideal tumor models should recreate the 3D fibrillar IM microstructure and
geometry of cell-cell and cell-matrix associations to support physiologically relevant cell
phenotypes, as well as enable mechanistic study through matrix tunability [12,13,38].
Unfortunately, many models fail to replicate these critical features of 3D tumor-ECM
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interactions and give rise to contradictory results. For example, breast cancer cells cultured ontop of Matrigel- or type I collagen-coated polyacrylamide (PA) gels showed that increased PA
concentration (stiffness) enhanced EMT [51,52], while breast cancer and glioblastoma spheroids
embedded within 3D fibrillar type I collagen matrices showed decreased mesenchymal behavior
and invasiveness with increased collagen concentration (stiffness) [53–55]. These examples
showcase how different geometries of cell-matrix interactions and ECM microstructures can
yield conflicting results. Clearly, the ability to recreate ECM architecture and physical properties
experienced by cancer cells in vivo will contribute to a more complete understanding of EMT
and invasion.
Over the last several years, our laboratory has worked to develop new tools and methods
for mechanistic study of fibrillar type I collagen self-assembly and the impact of resultant matrix
physical properties on cell phenotype, function, and tissue morphogenesis. As part of this effort,
we identified and standardized (ASTM F3089-14) a new soluble collagen subdomain (Oligomer)
that retains natural, mature intermolecular crosslinks as well as the uncommon capacity for
suprafibrillar self-assembly [18,56]. Oligomer displays rapid self-assembly (polymerization) in
vitro and in vivo, forming highly-interconnected, D-banded collagen-fibril networks, which are
similar to those found in tissues in vivo. This collagen formulation supports systematic
modulation of the physical and biological properties of 3D IM microenvironments beyond what
can be achieved with conventional collagen monomer formulations [18]. The tunable and robust
matrices formed with Oligomer have proven useful in a variety of in-vitro applications including
mesenchymal stem cell differentiation, vascular network formation, glioblastoma migration, and
tissue engineering [55,57–59]. Type I oligomeric collagen (Oligomer) offers a promising
alternative to materials traditionally used to mimic the IM in 3D cancer models.
The goal of the present work was to develop and apply an in-vitro 3D tumor-ECM model
relevant to PDAC to further define the importance of ECM composition and physical properties
in guiding EMT. Three well-characterized PDAC lines representing points along the EMT
phenotypic spectrum were embedded within 3D self-assembled ECM microenvironments of
defined composition and physical properties and changes in their phenotype evaluated. For this
work, Oligomer was used to recreate the IM, and Matrigel, a reconstituted BM isolated from
Engelbreth-Holm-Swarm (EHS) mouse sarcomas (a tumor rich in basement membrane) [19] was
used to mimic the BM. Matrigel is routinely used to approximate a BM-like environment since
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it provides a complex mixture of macromolecules including laminin, type IV collagen, and
enactin. However, limitations associated with Matrigel include: 1) poorly defined molecular
composition, 2) lot-to-lot variability (protein concentration and molecular composition), and 3)
inability to recapitulate the specific nature of the biochemical and biophysical environment
associated with all tumors (lacks type I collagen and in-vivo cross-linking) [19,60]. Overall, our
results revealed a spectrum of matrix-driven phenotypes that were dependent on ECM
composition, fibril architecture, and initial cell phenotype. In general, non-fibrillar BM
(Matrigel) promoted epithelial behaviors such as clustered cell growth and E-cadherin
expression. In low density Oligomer, the exposure to fibrillar IM promoted EMT of a
subpopulation of epithelial BxPC-3 cells, while mesenchymal MiaPaca-2 cells more uniformly
displayed mesenchymal characteristics. Interestingly, for all PDAC lines, increasing IM fibril
density, which represents increasing desmoplasia, resulted in confined clustered growth due to
the increased spatial constraints and matrix stiffness. Comparison of ours results to those from
other in-vitro models highlight the importance of ECM composition, microstructure, and
mechanical properties in 3D in-vitro cancer models and establish Oligomer as a powerful tool in
cancer research for mechanistic study of tumor-ECM interactions.

Materials and Methods
2.2.1 Cell culture
BxPC-3, Panc-1, and MiaPaCa-2 cell lines were all obtained from American Type
Culture Collection (ATCC, Manassas, VA) and maintained per manufacturer guidelines. BxPC-3
cells were grown in RPMI-1640 (Life Technologies, Grand Island, NY) and Panc-1 and
MiaPaCa-2 cells were grown in high glucose DMEM (Hyclone, Logan, UT), all supplemented
with 10% heat inactivated fetal bovine serum (HI FBS; Life Technologies), 100 U/mL penicillin,
and 100 μg/mL streptomycin (Sigma Aldrich, St. Louis, MO). Growth medium of MiaPaCa-2
cells was additionally supplemented with 2.5% horse serum (Sigma Aldrich). Cells were
maintained in a humidified environment of 5% CO2 in air at 37°C, passaged at 70-80%
confluency, and used in experiments at passage numbers between 6 and 14.
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2.2.2 Creating in-vitro 3D tumor-ECM models
Type I oligomeric collagen was extracted from the dermis of market weight pigs (Beutler
Meat Processing, Lafayette, IN) using acid solubilization as previously described [23]. Pig hides
for this extraction process were obtained from a commercial meat-processing source according to
Purdue University Animal Care and Use Committee (PACUC) guidelines, though specific
approval was not needed. Extracted collagen was lyophilized for storage, dissolved in 0.01 N
hydrochloric acid (HCl) for use, and standardized according to ASTM International Standard
F3089-14 [30]. Briefly, Oligomer formulations were standardized based on molecular
composition and polymerization capacity which is defined by the relationship between shear
storage modulus (G’, Pa) of the polymerized matrix as a function of Oligomer concentration.
Growth Factor Reduced Matrigel (Corning Life Sciences, Tewksbury, MA) was stored at -20°C
and thawed at 4°C or on ice before use. Since Matrigel is known to have high batch-to-batch
variability [28,31], all drug dosing experiments were performed with the same lot.
In-vitro 3D tumor-ECM models were created by encapsulating tumor cells within various
reconstituted matrix compositions at 2x105 cells/mL. Matrigel was used undiluted, while
Oligomer was diluted with 0.01 N HCl to desired concentrations and neutralized (pH=7.4) with
10X phosphate-buffered saline (PBS) and 0.1 N sodium hydroxide as previously described [25].
To create matrices with different Oligomer:Matrigel ratios, neutralized Oligomer solution (0.9
mg/mL) and Matrigel solutions were admixed at the following ratios—100:0, 75:25, 50:50,
25:75, 0:100 (volume:volume). To determine the effect of IM physical properties on EMT,
Oligomer-only matrices were prepared at concentrations of 0.9, 1.5, 2.1 mg/mL which
corresponded to shear storage modulus (matrix stiffness) values of approximately 100-, 500- and
1000 Pa. We have previously established that a positive correlation exists between Oligomer
concentration, fibril density, and matrix stiffness [23,25,32]. 3D constructs were created by
aliquoting matrix-cell suspensions (100 μL, 2x105 cells/mL) into a 96 well plate followed by
incubation at 37°C for 20-30 minutes to induce matrix polymerization or self-assembly.
Immediately following self-assembly, the appropriate cell culture medium was added and
constructs were cultured for four days with medium changes every other day.
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2.2.3 Viscoelastic testing
Viscoelastic properties of matrices were determined using oscillatory shear mode on an
AR2000 rheometer (TA Instruments, New Castle, DE) as previously described [23]. Samples
were polymerized on the rheometer stage for 30 min followed by a shear-strain sweep from 0.1%
to 4% strain at 1 Hz. The shear storage modulus (G’) at 1% strain was used as a measure of
matrix stiffness. Each sample was tested in triplicate (n=3).
2.2.4 Staining and imaging
Tumor-ECM constructs were fixed in 3% paraformaldehyde (Mallinckrodt, Derbyshire,
UK) and permeabilized using 0.1% Triton X-100 (Sigma Aldrich). To visualize cell morphology,
F-actin was stained with Alexa Fluor 488 phalloidin (Life Technologies). For immunostaining,
constructs were blocked with 1% bovine serum albumin (Jackson ImmunoResearch, West
Grove, PA), followed by overnight incubation at 4°C with goat anti-rabbit primary antibodies for
vimentin and E-cadherin (D21H3 and 24E10, Cell Signaling Technologies, Danvers, MA). After
rinsing with 1X PBS, constructs were incubated overnight at 4°C with anti-rabbit conjugated
Alexa Fluor 488 secondary antibody (A12379, Life Technologies) followed by nuclear
counterstaining with Draq5 (Life Technologies).
Images were collected using laser scanning confocal microscopy on an Olympus IX81
inverted microscope with an Olympus Fluoview FV1000 system (Olympus, Tokyo, Japan).
Image stacks of 150-200 µm thickness with a 5 µm step size were obtained using a 20X air or
60X water objective, and z-projections were created using Imaris software (Bitplane, Concord,
MA). Confocal reflection microscopy was used to visualize the collagen-fibril microstructure
[33].
2.2.5 Western blotting
Western blots were used to determine EMT protein expression on a population level for
BxPC-3 and MiaPaca-2 in 2D and within constructs of varied Oligomer stiffness and
Oligomer:Matrigel ratios. Cell lysates from 2D culture were obtained directly from cell culture
flasks at 70-80% confluency using chilled 1X RIPA buffer (Millipore, Bedford, Massachusetts)
containing 0.2% halt phosphatase and protease inhibitor cocktail (Thermo Fisher Scientific,
Waltham, MA), and 2% phenylmethanesulfonyl fluoride solution (Sigma-Aldrich; 2%). Lysates
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from 3D culture were obtained by snap freezing constructs after four days of culture, grinding
them into a powder, and dissolving in lysis buffer. All samples were kept on ice with periodic
vortexing for one hour for 2D samples and three hours for 3D samples. Total protein
concentration for all samples was determined using a BCA protein analysis kit (Pierce,
Rockford, Illinois). Samples containing 30 µg of protein were loaded onto a 4-20% Tris-HCl
pre-cast gels (Bio-Rad, Hercules, CA) and transferred onto Trans-Blot Turbo Midi Nitrocellulose
membranes (Bio-Rad). After blocking in SEA BLOCK Blocking Buffer (Thermo Fisher
Scientific) overnight at 4° C, the membranes were incubated with mouse antibodies against Ecadherin (Cell Signaling Technology, 1:1000), fibronectin (BD Biosciences, San Jose, CA;
1:1000), and vimentin (BD Biosciences; 1:1000) overnight at 4° C. Mouse antibody against
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Meridian Life Science, Memphis, TN;
1:1000) was used as a loading control. Membranes were then washed in 1X PBS with 0.05%
Tween-20 (Sigma-Aldrich) and incubated for two hours at room temperature with horseradishperoxidase–conjugated IRDye 800CW anti-mouse secondary antibody (LI-COR Biosciences,
Lincoln, NE; 1:10000). After multiple washes with the PBS/Tween solution, bands were
visualized using Odyssey CLx Infrared Imaging System (LI-COR).
2.2.6 Determining gemcitabine sensitivity
PDAC cell sensitivity to gemcitabine (Santa Cruz Biotechnology, Dallas, TX) was
determined by dosing with a 10-point drug dilution (1:5 dilution starting at 200 μM) and
calculating IC50 values from data obtained with Alamar Blue metabolic indicator (Invitrogen,
Frederick, MD). Cells were seeded in 96-well plates either on 2D tissue culture plastic at 4x103
cells/well or within different 3D matrix formulations at 2x105 cells/mL (100 µL or 2x104
cells/well). After 24 hours, culture medium was replaced with medium containing gemcitabine
dilutions, 20 μM staurosporine (positive kill control; Santa Cruz Biotechnology), or 1% DMSO
(negative control; Sigma Aldrich). Treatments were replenished after 48 hours. Each treatment
was performed in triplicate, and all experiments were repeated at least 3 times (N≥ 3; n=3).
After 72 hours of treatment, fresh medium containing 10% Alamar Blue solution and 1%
FBS was added to each well, and well-plates were incubated for an additional 8 hours.
Fluorescence intensity of medium was measured spectrofluorometrically using 530 nm/590 nm
excitation/emission on a SpectraMax M5 Microplate Reader (Molecular Devices, Sunnyvale,
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CA). Raw intensity values were normalized to the positive and negative controls with the
following equation: % 𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑙𝑖𝑡𝑦 = (I𝑛 − I𝑆𝑇𝑆 )⁄(I𝐷𝑀𝑆𝑂 − I𝑆𝑇𝑆 ) × 100%. In represents the
intensity value of the nth dilution. ISTS and IDMSO represent intensities recorded from positive kill
control and negative control, respectively. GraphPad Prism (GraphPad Software Inc., San Diego,
CA) was used to fit a four-parameter logistic curve. The automatic robust outlier detection
algorithm within Prism was used to detect and exclude outliers from the final fit. Reported values
represent relative IC50, defined as the halfway point between the bottom and top plateaus of
each curve.
2.2.7 S-phase fraction determination
Total cell number and the fraction of cells undergoing S-phase were determined using
Click-iT Edu (Life Technologies) followed by quantitative image analysis using Imaris
(Bitplane). Briefly, after 3 days of culture, tumor-ECM construct medium was refreshed with
medium containing 10 μM 5-ethynyl-2’-deoxyuridine (Edu) and cultured for another 24 hours.
Constructs were then fixed with 3% paraformaldehyde (Mallinckrodt), permeabilized using 0.1%
Triton X-100 (Sigma Aldrich), and incubated with Click-iT reaction cocktail prepared following
manufacturer’s instructions. Constructs were subsequently counterstained with Draq5 and zstack images of 50 μm thickness were collected using laser scanning confocal microscopy on an
Olympus IX81 inverted microscope with an Olympus Fluoview FV1000 system (Olympus) and
a 20X air objective. The Imaris spot detection algorithm was used to independently detect nuclei
stained with Click-iT Edu and Draq5 for quantification of the number of cells undergoing Sphase and total cell number, respectively. S-phase fraction was then calculated by dividing the
number of S-phase cells by the total number of cells. Images (2 per well) from two separate
experiments (N=2) performed in triplicate (n=3) for each matrix stiffness were used for final
calculations and statistics.
2.2.8 Statistical analysis
Statistical analyses were performed using SAS (Statistical Analysis System; SAS
Institute Inc., Cary, NC). For gemcitabine sensitivity, a two-factor ANOVA was used to compare
stromal ECM microenvironment and cell type. Main effects were compared using Tukeycorrected pairwise comparisons for one factor while holding the other factor constant. A one-
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factor ANOVA with Tukey-corrected pairwise comparisons was used to analyze viscoelastic
testing data. S-phase fraction data was analyzed with a three-factor ANOVA which included
experiment number and replicate as factors in order to test their significance and not falsely
inflate the degrees of freedom in the model. In all cases, differences were considered statistically
significant when p<0.05.

Results
2.3.1 Established PDAC lines cultured in 2D represent phenotypes along the EMT
spectrum
Throughout this work, three established PDAC lines with distinct EMT phenotypes were
used (BxPC-3 – epithelial, Panc-1 – intermediate, and MiaPaCa-2 – mesenchymal) to evaluate
ECM-guided EMT. Literature based characteristics of these PDAC lines are summarized in
Figure 2-2A. To validate each cell line’s initial phenotype, cell morphology and expression
patterns of EMT marker proteins, E-cadherin and vimentin [8,34], were determined following
2D culture. Here, we defined epithelial phenotype as cells growing in tight clusters with
prominent E-cadherin expression, high cell-cell interactions, and primarily cortical actin [35]. On
the other hand, mesenchymal phenotype was characterized by individual cells with spindleshaped morphology, prominent actin projections, high cell-ECM interactions, and pronounced
vimentin expression [35].
Consistent with previously published work [61,62], BxPC-3 cells displayed an epithelial
phenotype in 2D culture, growing as cell clusters with prominent E-cadherin expression, while
MiaPaCa-2 cells were mesenchymal, displaying the typical spindle-morphology with vimentin
expression (Figure 2-2B). Panc-1 cells exhibited an intermediate phenotype, growing as clusters
with some actin projections and expressing vimentin but not E-cadherin (Figure 2-2B). In
addition to phenotype, gemcitabine sensitivity was measured with relative IC50 values calculated
from 10-point dose response curves, showing that in 2D, Panc-1 cells were the most resistant to
gemcitabine, followed by BxPC-3, and then MiaPaCa-2 (Figure 2-2C). These results were
consistent with previously published studies where similar experimental conditions and assay
methods were employed (Appendix Table S 1).
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Figure 2-2 PDAC lines differ in EMT phenotype and gemcitabine resistance when cultured on 2D plastic.
(A) Table summarizing pancreatic cell line phenotype, patient derivation, and relevant mutations [122]. (B)
BxPC-3, Panc-1,and MiaPaCa-2 cells were cultured on 2D plastic (4x103 cells/well) for 4 days, stained for actin
(green), vimentin (red), E-cadherin (yellow), and nuclei (blue), and imaged using confocal microscopy. Images
represent z-stack projections (20 µm thickness; scale bar = 30 µm). (C) Gemcitabine IC50 values (mean  SD)
were determined from 10-point dose response curves for cell lines cultured on 2D plastic. Letters indicate
statistically different groups (p<0.05, n=5).

2.3.2 At matched stiffness, Oligomer induces EMT and Matrigel induces MET
The effect of various ECM ligands and soluble factors on tumor cell plasticity and EMT
phenotype is routinely studied for cells cultured on 2D surfaces [63–66]. However, less is known
regarding how cells sense and respond to 3D IM and BM environments with defined biochemical
and biophysical attributes [54,67,68]. Here, PDAC lines were cultured within 3D type I collagenfibril matrices prepared with Oligomer and tumor BM-like microenvironments prepared with
Matrigel. Since Oligomer and Matrigel represent different ECM compositions and
microstructures, an Oligomer concentration was chosen to yield matrix stiffness values that
matched undiluted Matrigel (G’=100 Pa), avoiding stiffness as a possible confounding variable.
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As summarized in Figure 2-3, the fibrillar type I collagen matrices formed by Oligomer
(100 Pa) promoted various degrees of EMT and mesenchymal behavior, while Matrigel induced
more MET and epithelial behavior. More specifically, when grown within Oligomer (100 Pa), all
PDAC lines showed decreased cell-cell associations and more pronounced spindle-shaped
morphology with prominent actin projections. A subset of BxPC-3 cells shifted to expressing
both vimentin and E-cadherin in Oligomer as detected by immunostaining, while both Panc-1
and MiaPaCa-2 cells only expressed vimentin. In contrast, all PDAC lines cultured within

Figure 2-3 Stromal ECM drives pancreatic cancer cell morphology and phenotype.
BxPC-3, Panc-1, and MiaPaCa-2 cells were cultured (2x105 cells/mL) for 4 days within Oligomer (0.9 mg/mL;
100 Pa) and Matrigel (100 Pa). Constructs were stained for actin (A; green), vimentin (B; red), E-cadherin (C;
yellow), and nuclei (blue) and imaged using confocal microscopy. Images represent z-stack projections (100 µm
thickness; scale bar = 30 µm). Yellow boxes represent 3X digitally zoomed sections (ii) and arrowheads note
prominent actin protrusions. (D) Table summarizing protein expression and morphological observations from
panels A-C.
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Matrigel grew as tight clusters with high nuclear to cytoplasmic ratios and cortical actin (Figure
2-3A). Additionally, within Matrigel, Panc-1 cells shifted to expressing both E-cadherin and
vimentin, while BxPC-3 and MiaPaCa-2 cells expressed E-cadherin only and vimentin only,
respectively (Figure 2-3B,C). Collectively, these results document that specific ECM ligands,
and their associated microstructures, are critical determinants of PDAC phenotype and behavior,
especially as it relates to EMT and MET.
2.3.3 Dose response analysis reveals matrix-dependent gemcitabine sensitivity of PDAC
lines
In high throughput 2D drug screening, IC50 is commonly used as a measure of drug
sensitivity. However, fewer studies report IC50 values for 3D culture models because adapting
drug dosing protocols and analyses to 3D formats tends to be more difficult, time consuming,
and resource intensive [11,69]. To demonstrate that our 3D tumor-ECM model is amenable to
medium and high throughput drug screening, the relative IC50 values of gemcitabine were
determined for each PDAC line within 3D Oligomer and Matrigel, prepared with matched matrix
stiffness. As shown in Figure 2-4, gemcitabine sensitivity of PDAC lines was matrix dependent.
When cultured within Oligomer (100 Pa), PDAC lines showed statistically similar (p>0.05) IC50
values, ranging from about 6 to 23 nM. In contrast, when cultured within Matrigel, Panc-1 cells

Figure 2-4 Sensitivity of PDAC lines to gemcitabine depends on 3D matrix type.
(A) Table and (B) graph summarizing gemcitabine IC50 values (mean  SD) for PDAC lines cultured (2x105
cells/mL) for 4 days within Oligomer (0.9 mg/mL, 100 Pa) or Matrigel (100 Pa). Asterisk (*) indicates
statistically different groups (p<0.05, N=3-4, n=3).
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displayed a significantly (p<0.05) higher IC50 value of 72.841.3 nM compared to BxPC-3 and
MiaPaCa-2 cells which measured 18.312.9 nM and 15.42.8 nM, respectively. Further, IC50
values for BxPC-3 and MiaPaCa-2 cells in Matrigel were statistically similar (p>0.05) to those
obtained for Oligomer (100 Pa), while Panc-1 cells’ IC50 was significantly lower (p<0.05) in
Oligomer compared to Matrigel. It is worth noting that Panc-1 cells showed greater resistance to
gemcitabine compared to the other PDAC lines when cultured within Matrigel (Figure 2-4) and
on plastic (Figure 2-2C), but not within Oligomer. Collectively, these results emphasize that the
tumor microenvironment, including ECM composition and microstructure, is a critical
determinant of PDAC drug sensitivity.
2.3.4 Varying stromal IM to BM ratio guides PDAC phenotype and EMT
As tumor cells become exposed to fibrillar type I collagen, whether deposited by stromal
cells or encountered at the tumor-tissue interface, cells may simultaneously interact with both IM
and BM components, thus engaging different integrin receptors [70,71]. To define how such
dynamic cell-ECM signaling affects PDAC phenotype and EMT, PDAC cells were cultured
within matrices prepared with different ratios of Oligomer and Matrigel, representing IM and
BM, respectively. These experiments were conducted with only two PDAC lines, BxPC-3 and
MiaPaCa-2, representing epithelial and mesenchymal phenotypes.
Matrix microstructure and stiffness were defined to determine how varying
Oligomer:Matrigel (IM:BM) ratio altered matrix self-assembly and physical properties (Figure
2-5). As visualized by confocal reflectance microscopy, matrix architecture varied from the
highly- branched fibrillar network for Oligomer (100:0) to no visible fibril microstructure in
Matrigel (0:100), emphasizing differences in self-assembly capacity and matrix physical
properties. Fibril density and length appeared to decrease with decreasing Oligomer:Matrigel
ratio with 100:0 and 75:25 displaying dense branched fibril networks and 50:50 and 25:75
exhibiting fewer and shorter fibrils. Observed differences in microstructure were consistent with
measured alterations in matrix mechanical properties. More specifically, matrix stiffness (G’)
values for 100:0 and 75:25 were statistically similar (p>0.05) while 50:50 and 25:75 were
significantly softer (p< 0.05). As expected for this experiment, 0:100 (Matrigel) and 100:0
(Oligomer) stiffness values were statistically similar (p>0.05), since Oligomer concentration was
chosen to match the stiffness of undiluted Matrigel.
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Figure 2-5 Oligomer:Matrigel ratio affects matrix microstructure and stiffness.
(A) Images represent z-stack projections (10 µm thickness; scale bar = 10 μm) from confocal reflection
microscopy of matrices prepared with varying Oligomer:Matrigel ratios. (B) Matrix stiffness values are given as
shear storage modulus (G’; mean  SD). Letters indicate statistically different groups (p < 0.05, n=3).

Analysis of PDAC cell morphology and protein expression as a function of
Oligomer:Matrigel ratio further supported the supposition that Oligomer induced EMT and
Matrigel induced MET to an extent that was dependent upon initial PDAC cell phenotype. As the
Oligomer:Matrigel ratio increased, an increased number of BxPC-3 cells transitioned from an
epithelial morphology to smaller cell clusters or individual cells displaying prominent
cytoplasmic projections (Figure 2-6A). In addition, these subpopulations showed an apparent
increase in vimentin expression and decreased E-cadherin expression as the Oligomer:Matrigel
ratio increased. Interesting these differences in maker protein expression were not observed
when measured at a population level via western blots which showed no change in E-cadherin
expression and no detectable vimentin expression with changing ratios (Figure 2-7). Modest
fibronectin expression was observed in BxPC-3 cells cultured in 100:0, but expression decreased
to undetectable levels once Matrigel was introduced into the construct.
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Figure 2-6 Oligomer:Matrigel ratio modulates EMT phenotype.
(A) BxPC-3 and (B) MiaPaCa-2 cells were cultured (2x105 cells/mL) within 3D matrices prepared with various
Oligomer:Matrigel ratios for 4 days. Constructs were stained for actin (green), vimentin (red), E-cadherin
(yellow), and nuclei (blue) and imaged using confocal microscopy. Images represent z-stack projections (100
µm thickness; scale bar = 30 µm).
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Figure 2-7 Oligomer:Matrigel ratio has phenotype-dependent effect on population-level protein expression.
Western blots showing EMT protein expression for BxPC-3 and MiaPaCa-2 (2x105 cells/mL) cultured for 4 days
within 3D matrices prepared at various Oligomer:Matrigel ratios.

MiaPaCa-2 cells, on the other hand, showed more drastic changes in morphology (Figure
2-6B) and population-level protein expression (Figure 2-7) with varying Oligomer:Matrigel
ratio, while immunostaining revealed only modest changes in EMT protein expression patterns
(Figure 2-6B). Within the lowest Oligomer:Matrigel ratios (0:100 and 25:75), MiaPaCa-2 cells
were tightly packed with little to no actin projections. As Oligomer content increased, cells
became progressively more singular and spindle-shaped, with cells in 75:25 aligning into
networks resembling the invasive front of a tumor. Immunostained MiaPaCa-2 cells did not
express detectable E-cadherin in any matrix composition. While vimentin expression was
observed in all matrices, it appeared to be reduced within 0:100 and 25:75 and shifted from
uniformly distributed throughout the cytoplasm to localized around cell nuclei. Analysis by
western blot confirmed immunostaining results with Oligomer:Matrigel ratio showing having no
effect on MiaPaCa-2 E-cadherin expression and vimentin expression decreasing with Matrigel
content (Figure 2-7). A similar decreasing expression trend was observed for fibronectin with
highest expression levels occurring in MiaPaCa-2 cells cultured within 100:0. Altogether, these
results suggest that i) a combination of IM and BM interactions plays an important role in
guiding tumor cell plasticity and EMT, and ii) ECM type and microstructure differentially
regulate cell phenotype depending on the cells’ initial EMT status.
2.3.5 Increasing collagen-fibril density (matrix stiffness) controls mesenchymal behavior
and suggests matrix dependent correlation between S-phase fraction and drug
sensitivity
Pancreatic cancer is known for significant desmoplasia, characterized by over-active
stellate cells and fibroblasts which increase fibrillar type I collagen deposition [32,33]. However,

22
the precise role played by desmoplasia and type I collagen in tumor-stromal ECM interactions
and tumor progression remains uncertain [40,72,73]. In order to better define the role of IM
physical properties in regulating EMT and drug sensitivity, matrix stiffness was varied by
altering the Oligomer concentration or fibril density as seen in Figure 2-8A and B. The positive

Figure 2-8 Stromal interstitial matrix stiffness alters PDAC cell phenotype.
(A) Matrix stiffness values of matrices prepared at Oligomer concentrations of 0.9, 1.5, 2.1 mg/mL are given as
shear storage modulus (G’; mean ± SD) with letters indicating statistically different groups (p < 0.05, n=3). (B)
Images represent z-stack projections of confocal reflection microscopy (10 μm thickness, scale bar = 10 μm) of
matrices (C) BxPC-3 and (D) MiaPaCa-2 cells were cultured (2x105 cells/mL) within these three matrices for 4
days. Constructs were stained for actin (green), vimentin (red), E-cadherin (yellow), and nuclei (blue) and
imaged using confocal microscopy. Images represent z-stack projections (100 µm thickness; scale bar = 30 µm).
(E) Western blot measurement of EMT protein expression for BxPC-3 and MiaPaCa-2 cultured for 4 days
within various Oligomer matrices and on 2D tissue culture plastic
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correlation between oligomer concentration, fibril density, and matrix stiffness has been
established previously [18,57,74]. PDAC lines were cultured within Oligomer matrices prepared
with stiffness values of 100, 500, and 1000 Pa and analyzed for changes in phenotype, S-phase
fraction, and gemcitabine sensitivity. The S-phase fraction was quantified since gemcitabine
causes checkpoint arrest and cell death by incorporating into DNA during S-phase [75].
When cultured in low stiffness (100 Pa) Oligomer, a significant subpopulation of BxPC-3
and nearly all MiaPaCa-2 cells took on a spindle-shaped, mesenchymal morphology. However,
as Oligomer density and stiffness increased, both cell types grew as clustered aggregates,
displaying more epithelial-like behavior (Figure 2-8C,D). Western blot data showed no
appreciable changes in EMT marker protein expression as a function of Oligomer stiffness
(Figure 2-8E). BxPC-3 expressed E-cadherin in the majority of cells in immunostained samples
and also showed prominent bands for E-cadherin. On the other hand, while immunostaining
showed vimentin expression in some BxPC-3 cells, expression was not detectable in western
blots. Conversely, MiaPaCa-2 showed vimentin expression with no E-cadherin expression in all
conditions in both immunostaining and western blots. Both lines showed fibronectin expression
under each condition, though bands for BxPC-3 were very faint. Compared to cells cultured on
2D, Oligomer appeared to promote fibronectin expression in BxPC-3 and both fibronectin and
vimentin expression in MiaPaCa-2 (Figure 2-8E). It is noteworthy that this upregulation was
observed even though GAPDH (loading control) for 2D samples appeared heavier, despite
efforts to load equal protein amounts for all samples. The heavier banding for 2D samples is
likely due to some residual matrix protein in 3D samples, which would effectively decrease the
ratio of cellular protein to total protein for 3D samples compared to 2D samples.
Finally, gemcitabine sensitivity and S-phase fraction were measured for BxPC-3 and
MiaPaCa-2 cells within Oligomer of varied stiffness. Only IC50 values for BxPC-3 in 100 Pa
were statistically (p<0.05) different from 500 Pa and 1000 Pa; however, both lines showed
apparent inverted bell-shaped relationships with minima at 500 Pa (Figure 2-9A). Interestingly,
these minima in gemcitabine sensitivity appeared to correlate with maxima in S-phase fraction,
also at 500 Pa, albeit with no statistical significance (Figure 2-9B). Overall, these results show
that matrix stiffness, altered through changing fibril density, can be a regulating factor in not
only EMT, but also cell cycle progression and drug sensitivity.
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Figure 2-9 Stromal interstitial matrix stiffness alters PDAC gemcitabine sensitivity and proliferative
capacity.
(A) Gemcitabine IC50 values (mean  SD; n=3) and (B) S-phase fraction (mean  SD; N=2, n=3) for BxPC-3
and MiaPaCa-2 cells cultured for 4 days within 3D Oligomer (2x10 5 cells/mL) prepared at stiffness values of
100 Pa (0.9 mg/mL), 500 Pa (2 mg/mL), and 1000 Pa (3 mg/mL). Asterisk (*) indicates statistically different
groups (p<0.05); note that values between different cell types were not compared.

Discussion
In-vitro tumor models provide important basic research and drug screening tools;
however, few adequately recreate metastasis and associated EMT, which remains the major
cause of PDAC and other cancer-related deaths. The present work focused on 3D tumor-ECM
model development, emphasizing the need for more accurate recapitulation of the PDAC
desmoplastic ECM composition and microstructure, which is typically characterized by high
levels of fibrillar type I collagen [76]. This fibrous, stiff ECM microenvironment is generally
thought to compromise drug transport, decrease tumor chemosensitivity, and enhance EMT and
tumor invasion [39,41,77]. However, our 3D tumor-ECM model revealed that PDAC phenotype
and behavior vary significantly with initial tumor cell phenotype and depend largely on both the
biochemical and biophysical properties of the surrounding stromal ECM. Although fibrillar type
I collagen was found to generally promote enhanced expression of specific mesenchymal marker
proteins, PDAC morphology as well as the extent of cell-ECM interactions and phenotypic
heterogeneity were largely determined by matrix biophysical properties, namely fibril density
and associated matrix stiffness. Such results are consistent with recent in-vivo preclinical studies
that have shown dense type I collagen-fibril architectures restrain rather than promote PDAC
EMT and metastasis [78,79].
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The PDAC stromal ECM is comprised of BM and IM–two ECM types that differ
substantially in their molecular composition, microstructure, and viscoelastic properties [80,81].
BM provides a thin, mechanically weak barrier that separates epithelium (e.g., glands, ducts) and
endothelium (e.g., blood vessels, lymph vessels) from underlying interstitial tissues. It is
primarily composed of type IV collagen which forms highly intertwined supramolecular
networks with laminin, entactin, nidogen, and other molecules [82]. In contrast, IM is primarily
composed of type I collagen which exhibits hierarchical self-assembly to form the D-banded
fibrillar architecture of interstitial connective tissues. During IM synthesis and fibril selfassembly, intermolecular cross-links form between collagen molecules by an enzyme-mediated
process, imparting significant stability and strength to the fibrillar matrix [83]. These two ECM
types are of particular interest to PDAC because poor patient prognosis has been correlated with
a decrease in BM proteins and a corresponding increase in IM content [76,84].
In the present work, Matrigel was used to approximate the BM, and Oligomer was used
to recreate and tune the fibrillar IM microenvironment. While no research tools exist today that
allow accurate BM recreation in vitro, Matrigel, a murine tumor BM extract, has been used
extensively to mimic the BM in 3D cancer models. Although Matrigel as a natural hydrogel
formulation contains many BM components, it does not exhibit the molecular cross-linking or
architecture found in BM in vivo and shows significant lot-to-lot variability and low mechanical
properties [80,85]. Oligomer, on the other hand, is a soluble type I collagen subdomain that,
unlike conventional monomer formulations (atelocollagen and telocollagen), retains mature
intermolecular cross-links formed in vivo [57]. As a result, this formulation exhibits high-order
supramolecular assembly, giving rise to highly branched fibril networks with significantly
improved physiological relevance, mechanical integrity, and resistance to proteolytic degradation
[18,56,74,86]. Because Oligomer is standardized based upon its self-assembly or fibril-forming
capacity, it supports tunability over a broad range of fibril microstructures and matrix stiffness
values and shows excellent reproducibility within and between laboratories [18,74]. The distinct
self-assembly capacity of Oligomer has been documented in previous published work, where
polymerization of Oligomer over the concentration range of 0.5-4 mg/mL yields matrices with
G’ values of 40-1500 Pa while matrices prepared with telocollagen and atelocollagen,
formulations commonly used in other studies, cover G’ ranges of 2-300Pa and 2-50Pa,
respectively [18]. The use of Oligomer in the present work allowed PDAC cells to engage type I
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collagen IM in a natural fibrillar context with systematic control of fibril density and associated
matrix stiffness.
Table 2-1 summarizes various in-vitro tumor models used for EMT and invasion studies,
highlighting culture format, ECM scaffold material, and ECM biophysical properties as critical
design parameters for recreating pathophysiologically relevant cell-matrix interactions in vitro
[13,87]. Based on this review, the majority of EMT and invasion studies performed to date have
focused on breast cancer, underscoring a need for more pancreatic cancer investigations. Most
work targeting ECM-guided EMT has been performed using cell monolayers grown on either 2D
plastic surfaces with adsorbed matrix proteins or on-top of 3D substrates (also known as semi3D). On the other hand, studies focused on tumor invasion, a hallmark of metastasis, involve
embedding multi-cellular spheroids or organoids within 3D matrices prepared from monomeric
type I collagen. Although not addressed specifically in the table, this review also revealed that
culture format often dictates whether cellular or population level analyses are used and that 3D
embedment experiments often lack population level evaluations [68–70]. Finally, only one other
tumor EMT study was identified that involved 3D embedment of single cells within a fibrillar
type I collagen matrix, which is more representative of the tumor IM than Matrigel or
bioengineered hydrogels, such as those prepared from polyethylene glycol (PEG) or alginate.
These gaps are addressed, in part, by the present work.
Since modulation of the tumor ECM context and associated EMT are likely more of a
continuum rather than a binary change [88], the influence of ECM composition and
microstructure on tumor cell phenotypic transition was documented by varying IM:BM
(Oligomer: Matrigel) ratio while maintaining a constant matrix stiffness. Interestingly, when
three different PDAC lines were exposed separately to low-density Oligomer (100 Pa), they
maintained their mesenchymal phenotype or showed evidence of EMT, with resultant
morphology and protein expression profiles dependent upon initial cell line phenotype. On the
other hand, Matrigel (100 Pa) inhibited EMT, promoted a clustered morphology for all cell
types, and decreased mesenchymal protein expression. Such observations are consistent with the
general expectation that IM is associated with mesenchymal behavior, and BM is involved in
maintaining epithelial phenotype [89–91]. However, few in-vitro studies have demonstrated how
simultaneous interaction of tumor cells with IM and BM contributes to EMT and phenotypic
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Table 2-1 Models used to study role of ECM on EMT and invasion
Schematic and
Model
Cancer Type
Outcomes
Description
2D coatings
(molecular) • Non-fibrillar
• Type I collagen

• Fibrillar
• Type I collagen

pancreatic

• Type I collagen Oligomer promotes EMT of cells
with Smad4 deletion
• Matrigel promotes MET and hinders EMT
• Interaction with collagen fibrils and BM components
pancreatic
in Matrigel Increases invasive phenotype of
transitioned cells
• Increasing fibril density decrease mesenchymal
nature of cells

Present
work

breast

[91]

pancreatic

• Exposure to TGF- β1 and EGF is necessary for EMT
of cells grown in PEG hydrogels admixed with
molecular type I collagen

[92]

pancreatic

• Exposure to TGF-β1 Is necessary for EMT of cells
grown in RGD-alginate
• TGF- β1 removal results in EMT reversion (MET)

[93]

• Incorporating GFOGER peptide (α2β1 integrin
binding sequence) into PEG hydrogels increases
invasive phenotype

[68]

breast,
prostate, lung

breast

• Fibrillar
• Type I collagen

[63,64,66]

• Type I collagen monomer matrices promote invasive
phenotype
• Matrices with small amount of Matrigel promote
acinar morphology

3D single cell
embedment

• Non-fibrillar
• PEG or alginate
hydrogels

• Molecular type I collagen increases EMT via α2β1
integrin mediated E-cadherin downregulation and
vimentin upregulation

Ref.

breast

breast
Semi-3D
(3D on top)

• Larger fibril diameter leads to more spread, less
clustered phenotype
• Increasing fibril diameter and decreasing pore size
increase invasiveness
• Increasing fibril density of underlying collagen
produces more proliferative, invasive phenotype
• Type I collagen monomer matrices promotes
mesenchymal phenotype
• Matrices with laminin and collagen combined
promote “invasive networks” of cells

[67]

[52]

[89]

breast

• Increasing stiffness of type I collagen monomer- or
Matrigel-coated polyacrylamide induces EMT

[51]

breast

• Increasing stiffness of Matrigel-coated
polyacrylamide promotes a more invasive phenotype
and loss of regular epithelial organization

[52]

lung

• Increasing stiffness of fibronectin-coated substrates
increases EMT
• Inhibiting cell contractility abrogates this relationship
suggesting contractile machinery is necessary for
EMT

[94]

• Non-fibrillar
• ECM-coated
Polyacrylamide
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(Table 2-1 continued)
Model

Schematic and
Description

Cancer Type

Outcomes

Ref.

breast

• Increasing fibril density of type I collagen monomer
matrices decreases spheroid invasiveness

[53]

breast

• Maximum invasiveness and loss of epithelial
organization occurs at intermediate density (stiffness)
of type I collagen monomer matrices

[95]

• Maximum invasiveness occurs within mixture of
breast
3D spheroid
Matrigel and type I collagen
or organoid
• Maximum invasiveness occurs at intermediate
embedment • Fibrillar
glioblastoma
stiffness of type I collagen Oligomer matrices
• Type I collagen
• Cells were most invasive and most sensitive to drugs
breast
going into low fibril density matrix (type I collagen
monomer)
breast

• Compared to Matrigel, type I collagen monomer
increased invasiveness and mesenchymal phenotype
of organoids

[96]
[55]

[54]

[90]

Note: EMT – Epithelial to Mesenchymal transition; MET – mesenchymal to epithelial transition; TGF-β1 –
transforming growth factor β1; EGF – epidermal growth factor; PEG – Polyethylene glycol; RGD – Arginine
Glycine-Aspartic acid

heterogeneity. Those studies that have done so, did not examine matrix microstructure and
mechanics or compare different cell lines across the EMT spectrum [89,91,96].
In the present work, Matrigel induced epithelial BxPC-3 cells to grow as tight clusters,
even when it was present in small amounts together with fibrillar type I collagen. Only in the
100:0 ratio, which had no Matrigel, did a subset of BxPC-3 undergo EMT, as indicated by a
subpopulation of cells demonstrating spindle-shaped morphology, prominent vimentin staining,
and some loss of E-cadherin staining. Population analysis by western blots supported the notion
of matrix-induced EMT heterogeneity with little change in vimentin or E-cadherin expression
and faint upregulation of fibronectin, another common marker for the mesenchymal phenotype.
These findings for the epithelial PDAC line are consistent with a recent study where embedded
normal mammary epithelial cells, MCF-10, only appeared invasive in monomeric type I collagen
matrices [91]. When even small amounts of Matrigel were added to type I collagen matrices,
MCF-10 displayed a more epithelial acinar phenotype.
On the other side of the EMT spectrum, MiaPaCa-2, which are classified as
mesenchymal, showed more drastic morphological changes, as well as a decrease in
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mesenchymal protein expression as IM:BM ratio increased. An interesting observation was that
combined IM and BM interactions in the 75:25 ratio appeared to promote a more invasive,
elongated morphology than IM alone. Benton and colleagues reported similar findings with
mesenchymal breast cancer cells, MDA-MB-231, which displayed the most invasive, migratory
phenotypes when cultured on-top or embedded as spheroids within matrices prepared from
monomeric type I collagen and Matrigel [89,96]. Although the above-mentioned studies did not
evaluate the matrix physical properties of IM-BM combinations, we noted that the 75:25 ratio
was the only mixture of IM and BM that maintained the branched fibrillar architecture of type I
collagen and the associated matrix stiffness (100 Pa). In summary, these observations suggest
that for epithelial cells, Matrigel promotes epithelial morphogenesis regardless of the presence of
an interconnected collagen fibrillar matrix, but for mesenchymal tumor cells, a stable,
interconnected collagen fibrillar matrix with sufficient mechanical integrity is a primary factor in
driving invasive phenotypes. These results also point to the need for further work to define how
complex cell-ECM interactions such as those found at the tumor-stroma interface contribute to
phenotypic heterogeneity and the continuum of EMT phenotypes observed in vivo [97].
Comparisons between our results and those in Fig 10 also revealed that the manner in
which cells sense and respond to changes in substrate stiffness is highly dependent on the invitro model format (e.g., coated 2D, semi-3D, 3D embedded). Our results showed promotion of
EMT and mesenchymal characteristics (e.g. spindle-shaped morphologies, vimentin and
fibronectin expression) in PDAC cells embedded within relatively low-density collagen fibril
matrices formed from Oligomer. When fibril density was increased, the resulting increased
matrix stiffness and spatial constraints hindered mesenchymal-like cell spreading and resulted in
confined, clustered growth. These results contradict observations from semi-3D models which
have shown cells on-top of soft substrates maintained epithelial characteristics (clustered growth,
E-cadherin expression, BM deposition) while increased substrate stiffness increased EMT-like
behaviors including cell spreading, migration, and vimentin or fibronectin expression
[51,52,94,98]. This trend was observed whether the underlying substrate on which cells were
cultured was fibrillar type I collagen or non-fibrillar coatings of molecular type I collagen,
Matrigel, or fibronectin on-top of PA gels. Therefore, the observed discrepancy between our
results and those of semi-3D models is likely due to differences in geometric constraints.
Specifically, the forced apical-basal polarization of cells imposed by semi-3D model geometry
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has been shown to alter the composition of cell-matrix adhesions and downstream signaling
pathways in a manner different than 3D embedment models [99,100]. Assuming that EMT
correlates with invasiveness, our results align more closely with those from 3D spheroid
embedment models in which the most invasive phenotypes were observed in either the lowest or
an intermediate stiffness type I collagen matrix while remaining more clustered at higher
stiffness [53–55,95]. These 3D embedment models, including the present work, demonstrate that
physical constraints experienced by cells within dense 3D matrices dominate over any increased
signaling that may occur from increased ligand density or increased substrate stiffness as
observed with semi-3D models. While some in-vitro studies aim to decouple matrix density and
stiffness through non-natural matrix crosslinking [91,101], the relevance of these methods
remains unclear since these two variables are naturally coupled with desmoplasia in vivo
[79,101]. Taken together, these comparisons highlight that when developing accurate in-vitro
tumor-ECM models, it is not just the presence of specific ECM ligands or “going 3D” that is
important, but one must consider culture geometry, ligand presentation, and fibrillar architecture
since all these features dictate EMT mechanobiology in vivo.
Our results also highlight two important, often overlooked aspects of 3D in-vitro models
– the cell-matrix tension balance and the collagen fibril architecture [99,102]. In cancer, loss of
cell-matrix tensional homeostasis and cell-induced alignment of type I collagen fibrils have been
implicated in tumor progression and invasion [38,52]. Specifically, researchers have shown that
increasing matrix tension by applying passive strain to monomeric type I collagen matrices
increased invasiveness of embedded mammary organoids [95]. On the other hand, relieving
intra-matrix tension by detaching similar collagen matrices from a culture dish caused mammary
epithelial cells to grow as tight acinar-like structures rather than the invasive, spindle-shaped
morphologies observed in attached matrices [91]. In the present work, the high levels of Matrigel
in low IM:BM ratios (50:50, 25:75) disrupted collagen fibril interconnectivity, which likely
hindered cells ability to generate force and create tensional strain within the matrix. These
mechanical changes, along with the BM signaling from Matrigel, are likely what caused
clustered cell growth of both cell lines in these matrices. On the other hand, the type I collagen
composition and interconnected fibril matrix of Oligomer (100:0) were sufficient to induce EMT
of BxPC-3. Contrary to this result, non-fibrillar hydrogels such as collagen-PEG or RGDalginate have been shown to not promote EMT in embedded pancreatic or breast cancer cells
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unless exogenous growth factors, such as TGF-1, were added [92,93]. It is important to note
here that bioengineered materials such as those fashioned from alginate or PEG have no inherent
bioactivity and lack physiologically relevant architecture. Even when molecular collagen (nonfibrillar) or RGD ligands are added to promote cell adhesion the architecture, mechanical
properties, and resultant cell-substrate interactions that occur within these artificial
microenvironments are dramatically different from those experienced by cells in vivo. From
these observations, it is clear that in-vitro models of tumor EMT and invasion should be designed
to accurately recreate ECM architectural features and cell-matrix mechanics for improved
correlation between in-vitro and in-vivo behavior [38,99].
In addition to highlighting the importance of collagen fibril architecture in mechanistic
study of tumor EMT and mechanobiology, observations from this work demonstrate the
translational potential of Oligomer-based tumor-ECM models. Oligomer is unique among type I
collagen formulations because of its purity, standardization, and ability for user customization,
making it a powerful tool for creating standardized 3D models [18,57,103]. Additionally, its
molecular make-up and its ability to form tissue-like collagen matrices with mature
intermolecular crosslinks make Oligomer an ideal material for predicting in-vivo outcomes
through recreating the ECM environment of desmoplastic tumors such as PDAC which are rich
in type I collagen [32,56,57,76]. In fact, the observed trend in increased EMT behavior with
decreased matrix density in the present work, has been recently noted in genetically engineered
mouse models of PDAC [78,79]. In these studies, reduced stromal cell activity led to decreased
desmoplasia and tumor stiffness which led to increased EMT, invasion and metastasis, as well as
lower overall survival rates. The matrix-induced EMT heterogeneity in low-density Oligomer
matrices is also reminiscent of observations from human clinical tumor samples in which only a
subpopulation of cells undergoes EMT [97,104]. Finally, although only minor significant
differences in drug sensitivity were found, this study demonstrates our ability to perform drug
dosing experiments and generate IC50 values for these 3D tumor-ECM models. Collectively,
these observations showcase the potential of Oligomer to serve as a robust platform for
mechanistic study of metastasis and creation of predictive 3D drug screening models.
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Conclusion
This work serves as a first step in the development of novel in-vitro 3D tumor-ECM
models where Oligomer is used as a standardized type I collagen formulation to recreate and
customize the IM component. From the foundational understanding of PDAC desmoplasia and
EMT gained from these experiments, we can now develop more complex models of pancreatic
and other cancers to systematically define the role of other prominent components of the tumor
stromal microenvironment and study tumor invasion in more detail. Additionally, the model of
matrix-driven EMT created by embedding PDAC cells within Oligomer-based fibril matrices
provides a useful tool that can be applied to further mechanistic study. Finally, by developing
and applying standardized in-vitro models with defined ECM microenvironments, we are
moving closer to accurately recreating tumor-stroma interactions and desmoplasia to provide
pathophysiologically relevant PDAC models which can be used for phenotypic drug screening to
ultimately predict therapeutic response and improve patient outcomes.
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3. DEVELOPMENT OF A NOVEL HIGH-THROUGHPUT, HIGHCONTENT PHENOTYPIC SCREENING MODEL FOR METASTASIS

Introduction
Despite progress in treating some cancers, metastatic tumors remain nearly impossible to
treat, thus metastasis continues to be the predominant cause of cancer-related deaths [25]. This
problem is especially apparent for highly metastatic cancers like pancreatic ductal
adenocarcinoma (PDAC), where approximately 90% of patients present with invasive or
metastatic disease [30]. While the lack of treatment options for patients with metastases
represents a multi-facetted problem, one of the biggest shortcomings is the lack of predictive
preclinical metastasis models that can be used for mechanistic studies and drug screening
[25,29]. Since metastasis involves tumor cell engagement, invasion, and remodeling of the
surrounding tissue extracellular matrix (ECM), it is becoming increasingly clear that accurate
recreation of such three-dimensional (3D) cell-ECM interactions and associated mechanobiology
is critical to the development of more predictive in-vitro models [35,105]. For PDAC, in
particular, fibrous connective tissue deposition mediated by cancer associated fibroblasts
(CAFs), known as desmoplasia, represents another tumor-associated change in ECM
composition and biophysical properties that has been associated with metastasis and implicated
as a negative prognostic indicator [76]. Altogether, this points to a need for preclinical metastasis
models that effectively recreate key features of tumor-stroma interactions such as those in PDAC
desmoplasia.
With this need in mind, it is also important to consider how the overall drug development
process informs preclinical model development. Pharmaceutical companies, in general, rely on
two main drug development strategies, specifically molecular target-based screening and
phenotypic screening [9]. Molecular target-based screening, which has been industry standard
for nearly 30 years, involves an identified molecular target (e.g., signaling protein) and
associated biochemical screens focused on protein-protein interactions or enzyme activity. This
process is extremely time and resource intensive because, by definition, one must know the
mechanism of action of both the disease-related molecular target and the candidate drugs at the
forefront of development. Phenotypic screening, on the other hand, begins with developing a
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disease model and associated assays focused on specific disease characteristics. One advantage
of this approach is that these phenotypic models are more physiologically relevant than models
used early in target-based screening since they are cell- or tissue-based rather than protein- or
enzyme-based. Further, phenotypic screening is an attractive strategy because it does not require
complete understanding of molecular mechanisms at the onset of drug development and is
conducive to drug repurposing screens [9]. Additionally, between 1999 and 2008, the majority of
newly approved drugs were developed using phenotypic screening despite target-based screening
being far more widely used in industry [7]. For these reasons, it has been suggested that
increased use of phenotypic screening may help reduce the high attrition rate of clinical trials and
should be the focus of preclinical model development [7,9,10].
When developing next-generation in-vitro phenotypic models of tumor metastasis, a
number of design criteria must be considered. Specifically, while there is advocacy that added
model complexity (inclusion of vasculature, various stromal and immune cells) may increase
pathophysiologic relevance and predictive power, such approaches fall short with respect to
practical logistics [22,23,106]. For such models to gain traction and widespread use within both
pharmaceutical and academic environments, they must also be user-friendly, time-efficient,
reproducible, standardizable, scalable, and ideally, amenable to high-throughput automation (e.g.
automated imaging systems, liquid handling robots) [23,36]. Additionally, to achieve their full
potential, phenotypic models should be combined with high-content multiplex optical analyses
rather than traditional population-level spectrophotometric measures of cell viability [36,107].
Finally, phenotypic model readouts should be correlated with in-vivo or clinical outcomes to
effectively support validation and translation of their predictive power [10,24]. While some
models meet a few of these criteria, there remains a paucity of model standardization and
validation in the published literature. Finally, few, if any, 3D in-vitro models achieve an
appropriate balance between pathophysiologic relevance and practical considerations to enable
translation to high-throughput, high-content (HT-HC) drug screening [22,23].
Conventional in-vitro metastasis models focus tumor cell migration and invasion [108].
Transwell (Boyden chambers), wound healing, and cell exclusion-zone assays represent the most
commonly used migration models, however the geometry and artificial constraints of these
models limit their physiologic relevance [108]. To better recreate tumor invasion, 3D spheroid
invasion models, where multicellular tumor spheroids are embedded within various 3D matrices,
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are becoming increasingly common [108–110]. However, adoption of these models as HT-HC
screening models is hampered by their lack of standardization and challenges associated with
scaling for high-throughput screening analyses. Specifically, these shortcomings include the
following: i) the time consuming nature of spheroid creation [36,108]; ii) the lack of user control
of spheroid size, shape, and cell density [21,111]; iii) the widespread use of Matrigel and
conventional monomeric type I collagen formulations giving rise to reproducibility issues and
questionable relevance of the ECM biophysical properties [112,113]; and iv) the inability to
reproducibly embed spheroid within 3D matrices [111]. To the best of our knowledge, there is
no phenotypic metastasis model which addresses the above-mentioned shortcomings by
supporting reproducible creation and embedment of customizable tumor spheres within a
standardized and customizable tissue ECM compartment (96-well format) for HT-HC
phenotypic screening.
To address the above-mentioned gap, the goal of this work was to develop a standardized
HT-HC phenotypic screening model of PDAC metastasis that is both pathophysiologically
relevant and practical to implement. The model was inspired, in part, by a “multi-tissue
interface” model that was originally developed for vasculogenesis/angiogenesis studies [114].
This model provides a high-degree of user customization and standardization, as it applies
standardized self-assembling type I oligomers for creation of two adjacent, independentlytunable tissue compartments (Figure 3-1A). To adapt and translate this model for HT-HC drug
screening, a custom-designed 96-well fabrication platform was created. This low-cost, 3Dprinted platform consists of an array of posts that supports rapid (within minutes) tumor sphere
formation and embedment (Figure 3-1B). The platform readily integrates with standard 96-well
culture plates making tumor sphere embedment within the surrounding tissue compartment user
friendly and highly reproducible (Figure 3-1C). Finally, this platform enables precision
placement of the sphere within the 3D tissue compartment, which is essential for integration with
automated 3D image collection via confocal microscopy. The present work represents the first
steps in verification and validation of this custom fabrication platform and the associated HT-HC
PDAC metastasis model for anti-cancer drug screening.
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A

B

(i)

Fabrication platform

(ii)

Schematic of 3D
metastasis model

Well-plate guide

Confocal Image of
3D metastasis model

C (i)

(ii)
Pipet spheres onto posts

(iii)

Pipet surrounding matrix into well-plate

(v)
Flip upright and incubate at 37 C to
polymerize surroundings

Invert and incubate at 37 C to polymerize spheres

(iv)

Lower prefilled well-plate onto spheres

(vi)
Remove fabrication platform and add medium

Figure 3-1 Overview of fabrication platform and 3D HT-HC metastasis model.
(A) (i) Schematic of 3D metastasis model and (ii) a representative image of tumor cells invading from the sphere
into the surrounding matrix. Image represents 16 fields of view, each of which is a maximum projection of a 400
μm z-stack (20 μm step; 21 slices) of a tumor sphere (Panc-1) after 5 days of culture; green = actin (phalloidin),
blue = nuclei (Hoechst 33342) and red = fibrillar collagen (confocal reflectance). (B) CAD drawing of customdesigned fabrication platform and associated well-plate guide which are used to rapidly and reproducibly create the
3D metastasis model. (C) Process diagram of experimental set up using fabrication platform. (i) Spheres are pipetted
onto the posts of the fabrication platform using a multi-channel pipet. (ii) Posts are covered with a 96-well plate and
incubated at 37 °C to allow for Oligomer self-assembly (polymerization). (iii) The wells of another 96-well plate are
filled with Oligomer solution which will serve as the surrounding matrix. (iv) After sphere polymerization, the
prefilled well plate is inverted and lowered onto the spheres (v) The plate is then flipped upright and incubated
again to polymerize surroundings. (vi) Fabrication platform is removed, and culture medium is added. Note: Well
plate guide is not shown in (C) but is used to aid in the placement of well-plates on-top of the fabrication platform.

Materials and Methods
3.2.1 Model development, optimization and validation
3.2.1.1 Cell culture
Established PDAC cell lines, BxPC-3 and Panc-1, were obtained from American Type
Culture Collection (Manassas, VA) and were grown in RPMI-1640 (Life Technologies, Grand
Island, NY) and high glucose DMEM (Hyclone, Logan, UT), respectively. Low-passage patient-
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derived PDAC cells, 10.05 and Pa03C, as well as the CAFs were grown in high glucose DMEM
without sodium pyruvate (Life Technologies). All medium was supplemented with 10% heat
inactivated fetal bovine serum (HI FBS; Life Technologies), and BxPC-3 and Panc-1 medium
was also supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin (Sigma Aldrich,
St. Louis, MO). Cells were maintained in a humidified environment of 5% CO2 in air at 37°C.
All cells were passed when they reached 70-90% confluency; established PDAC lines and CAFs
were used below passage 20 and patient-derived PDAC cells were used below passage 10.
3.2.1.2 Creation of 3D HT-HC metastasis model
Type I collagen Oligomer was derived from the dermis of market-weight pigs as
previously described [18]. Oligomer was dissolved in 0.01 N hydrochloric acid (HCl) and
standardized based on molecular composition and polymerization capacity according to ASTM
International Standard F3089-14 [103]. Polymerization capacity is defined as the relationship
between shear storage modulus (G’, Pa) of the self-assembled (polymerized) matrix and
Oligomer concentration. To achieve matrices of defined fibril density and matrix stiffness,
Oligomer was diluted with 0.01 N HCl to desired concentration and neutralized with a
proprietary 10X Self-Assembly Reagent. In this study, Oligomer matrices were prepared at
stiffness values of 200 and 500 Pa, which correspond to concentrations of approximately 1.5 and
2.3 mg/mL, respectively. Validation that the high cell density used for tumor-sphere formation
did not significantly alter Oligomer self-assembly capacity was performed with 1.5 mg/ml
matrices (data not shown).
The model fabrication platform was designed in Solid works (Dassault Systemes
Solidworks Corp., Waltham, MA) and 3D printed on a Fortus 400mc 3D Production System
(Stratasys, Eden Prairie, MN) using acrylonitrile butadiene styrene (ABS). Overall dimensions
and post spacing were optimized to accommodate glass-bottom 96-well plates (Cellvis,
Mountain View, CA). A well-plate guide was created to aid in uniform and controlled placement
of the spheres within all wells (Figure 3-1). The platform and well-plate guide were rendered
aseptic by spraying with 80% ethanol and ultraviolet light exposure. Model setup using the
fabrication platform is summarized in Figure 3-1C. First, to create tumor spheres, cells were
suspended in neutralized Oligomer at 1x107 cells/mL, and 5 μL drops were pipetted onto posts
with a multi-channel pipette. For co-culture experiments, CAFs were added to the Oligomer-cell
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suspension at a tumor cell to CAF ratio of 1:1 while maintaining an overall cell concentration of
1x107 cells/mL. Once spheres were pipetted onto the posts, the platform was covered with a 96well plate, inverted and incubated at 37°C for 8-10 min to allow Oligomer self-assembly. During
this incubation time, the wells of another 96-well plate were filled with 100 μL of Oligomer, and
once spheres were polymerized, this prefilled well plate was lowered onto the platform using the
well-plate guide to position the posts in the center of each well and embed spheres within
Oligomer. This well plate was then flipped upright and incubated again at 37°C for 15 min to
allow full polymerization of the surrounding matrix. Subsequently, the fabrication platform was
removed from the well plate and the appropriate medium added. Experiments comparing Panc-1
and BxPC-3 were cultured for 5 days while drug dosing experiments and those with patientderived lines were 4 days.
3.2.1.3 Analysis of metastatic phenotype: invasion and EMT
For invasion analysis, tissue constructs were fixed with 3% paraformaldehyde
(Mallinckrodt, Derbyshire, UK), permeabilized using 0.1% Triton X-100 (Sigma Aldrich), and
stained to visualize actin (Alex Flour 488 or 546 phalloidin; Life Technologies) and nuclei
(Draq5 or Hoechst 33342; Life Technologies). Images were collected using laser scanning
confocal microscopy with 10x objectives on either an Olympus IX81 inverted microscope with
an Olympus Fluoview FV1000 system (Olympus, Tokyo, Japan) or a Zeiss LSM 880 (Zeiss,
Oberkochen, Germany). Images were acquired such that the edge of the sphere was along one
edge of the image and took up approximately one quarter of the total imaging volume
(850×850×150 μm). To quantify tumor cell invasion, image analysis was performed on 3D
renderings of confocal image stacks using the “Cell” analysis package in Imaris (Bitplane,
Concord, MA). Briefly, the sphere boundary was defined by thresholding the phalloidin channel
to create an object of approximately 2 mm diameter. Nuclei of invading cells were identified by
creating 10 μm diameter spots (approximate diameter of average nucleus) using the Draq
5/Hoechst 33342 channel. The distance between the sphere boundary and every nucleus was then
calculated and any values less than zero were excluded. Batch processing was used to analyze all
images from a given experiment, followed by manual inspection and adjustment to ensure that
intensity thresholds appeared appropriate for each image. Data was used to calculate total
number of invading cells, average invasion distance, and maximum invasion distance. Two-
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factor ANOVA with Tukey-corrected pairwise comparisons (GraphPad Prism, GraphPad
Software Inc., San Diego, CA) were used to determine statistical differences (p< 0.05).
To analyze EMT protein expression constructs were also processed for immunostaining.
After fixation with 3% paraformaldehyde (Mallinckrodt), constructs were soaked in 30% sucrose
solution for 3 days, embedded in Optimum Cutting Temperature (OCT) compound (Fisher
Healthcare, Houston, TX), and frozen overnight at -80°C. Frozen constructs were sliced with a
Thermo Cyrotome FE (Thermo Fisher, Kalamazoo, MI) to create 60 µm cryosections that were
placed on Superfrost Plus glass slides (Thermo Scientific). Sections were blocked with 1%
bovine serum albumin (Jackson ImmunoResearch, West Grove, PA) followed by overnight
incubation at 4 °C with primary antibodies and 1 hour incubation at room temperature with
secondary antibodies. Slides were then rinsed and mounted using Fluro-Gel (Electron
Microscopy Sciences, Hatfield, PA). Primary antibodies included mouse anti-vimentin (V6389.
Sigma Aldrich) and rabbit anti-E-cadherin (24E10, Cell Signaling Technologies, Danvers, MA).
Alexa Fluor 405, 488, and 633 secondary antibodies (Life Technologies) of matched species
were used to visualize via immunofluorescence. Slides were counterstained with Hoechst 3342
(Life Technologies) for visualization of nuclei. Images were collected using laser scanning
confocal microscopy with 10x or 20x objectives on either an Olympus IX81 inverted microscope
with an Olympus Fluoview FV1000 system (Olympus, Tokyo, Japan) or a Zeiss LSM 880
(Zeiss, Oberkochen, Germany).
3.2.2 Proof of concept HT-HC screening
3.2.2.1 Drug dosing and high-content assay
For proof of concept HT-HC drug screening, medium containing drugs was added 24
hours after model setup, and refreshed every 24 hours thereafter for a total treatment time of 72
hours (3 days). Gemcitabine (Alfa Aesar, Tewksbury, MA) was applied as a standard 10-point
drug dilution with a starting concentration of 200 μM and a 1:5 dilution. Staurosporine (Alfa
Aesar ;20 μM) and DMSO (Sigma Aldrich; 1%) were used as kill and vehicle controls,
respectively. For the high-content assay, Click-iT Edu Alexa Flour 488 (ThermoFisher) and
MitoTracker Red CMXRos (ThermoFisher) were used to measure proliferation and metabolic
activity, respectively. Twenty-four hours prior to fixation, 10 μM 5-ethynyl-2’-deoxyuridine
(Edu) and 500 nM Mitotracker were added in serum-free medium along with the final drug
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treatment. After fixation with 3% paraformaldehyde (Mallinckrodt), constructs were rinsed with
1% BSA (in 1X PBS), permeabilized with 0.1% Triton X-100 (Sigma Aldrich), and incubated
overnight at 4°C with Click-iT reaction cocktail prepared according to manufacturer’s
instructions. Finally, constructs were counterstained with Hoescht 33342 (Life Technologies).
3.2.2.2 HT-HC imaging and analysis
Automated confocal imaging was performed using an Opera Phenix High-content
Screening System (Perkin Elmer, Waltham, MA). Imaging parameters, including exposure time,
laser power, and imaging depth were determined based on vehicle control wells and applied to
the entire well-plate. To capture the full diameter of the tumor sphere in addition to the
surrounding matrix, six fields of view from a 10X objective were obtained, with each field
representing a 500 μm confocal z-stack (25 μm per step size; 21 slices) which started at the
bottom of the sphere. Subsequent image analysis was performed in Harmony Software (Perkin
Elmer) using maximum intensity projections of tiled images to evaluate cell proliferation,
metabolic activity, and invasion (Supplemental Figure S 1). The first step of the analysis process
was detection and quantification of all cell nuclei. For invasion analysis, an image region was
created by blurring the Mitotracker channel with a gaussian filter, followed by thresholding to
create a “sphere region” approximately the same diameter as the whole sphere. The number of
invading cells was determined by subtracting the number of nuclei within the “sphere region”
from the total number of cells. Proliferative capacity was calculated by counting all Edu-labeled
nuclei and normalizing this number to the total number of nuclei in each image. To calculate
relative metabolic activity, the raw Mitotacker channel was thresholded to define a “metabolic
region,” and the fluorescent intensity of the Mitotracker channel was summed within this region.
The proliferative capacity, relative metabolic activity, and number of invading cells for
each well were then normalized to the kill and vehicle controls using the following equation:
% 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑠𝑒 = (A𝑛 − A𝑆𝑇𝑆 )⁄(A𝐷𝑀𝑆𝑂 − 𝐴𝑆𝑇𝑆 ) × 100%. An represents the value of the nth
dilution. ASTS and ADMSO represent values from kill control and vehicle control, respectively. This
data was used to fit three-parameter logistic curves in GraphPad Prism (GraphPad Software
Inc.), from which IC50 and Emax values were calculated. These values were obtained from three
independent experiments (N=3) and compared using a one-factor ANOVA with Tukey-corrected
pairwise comparisons. Differences were considered significant when p<0.05.
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Results
3.3.1 Fabrication platform supports user-friendly, rapid and reproducible model setup
3D spheroid invasion models suffer from a number of shortcomings including i) multiple
day setup, ii) lack of spheroid and ECM standardization and user control, and iii) inability to
accommodate automated HT-HC imaging [36,106,111]. Since a lack of standardized and
reproducible setup are at the foundation of these limitations, our goal was to design a platform
which facilitated rapid and reproducible creation of tumor spheres with precision embedment
within a surrounding type I collagen-fibril matrix. As shown in Figure 3-1, the platform consists
of an array of posts, specifically spaced to match dimensions of a standard 96-well plate. Post
tips were designed with a slight curvature to provide the necessary surface tension for sphere
fabrication, adhesion, and transfer. Post length was optimized along with a well plate guide so
that spheres were reproducibly and precisely positioned within the center of each well, 1 mm
from the well bottom in user-friendly fashion. These design features allowed the sphere to be
completely surrounded by matrix in a standardized location within the well-plate to facilitate
automated confocal imaging. When used in conjunction with a multi-channel pipette, this
platform supported rapid model setup within less than 30 minutes by various users in academic
and industrial laboratories. Overall, this simple yet novel design provides a user-friendly
interface for rapid, reproducible creation and embedment of tumor spheres, overcoming many of
the shortcomings of 3D spheroid invasion models.
3.3.2 Novel 3D metastasis model supports independent customization and optimization of
ECM biophysical properties of both tumor and surrounding tissue compartments
Another commonly mentioned shortcoming of 3D in-vitro cell culture models, in general,
is the lack of standardization and tunability of matrix composition and biophysical properties
[115]. Such user-control is desired for drug screening to optimize assay dynamic range, as well
as mechanistic mechanobiology studies. As stated previously, Oligomer, the type I collagen
formulation used in this study, is standardized based on its self-assembly capacity, with shear
storage modulus of the self-assembled matrix representing a quantifiable functional parameter
which has been correlated with oligomer concentration and fibril density [18,103]. Additionally,
Oligomer preserves the telopeptide ends of collagen triple helices and the natural intermolecular
crosslinks that exist in mature tissue collagen, leading to branched fibrillar matrices similar to
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Figure 3-2 Surrounding matrix density (stiffness) determines tumor cell invasiveness.
(A) Tumor spheres prepared with 200 and 500 Pa oligomeric collagen were seeded with 1x107 cells/mL (Panc1) and embedded within surrounding oligomeric matrices of 200 and 500 Pa and cultured for 5 days. Images
represent maximum projections of 150 μm confocal z-stacks; green = actin, blue = nuclei, scale bar = 100 μm.
(B) 3D tumor cell invasion from confocal images was quantified to create (i) a representative cumulative
distribution plot and calculate (ii) average number of invading and (iii) cells maximum invasion distance. (bars
represent mean ± std. dev., N=3, n=8-9; asterisks denote statistically different groups p<0.05)

those found in vivo and providing a much greater range of tunable matrix stiffness compared to
monomeric type I collagen formulations [18,56]. Because of its type I collagen composition,
Oligomer also serves as an accurate representation of the interstitial matrix laid down during
desmoplasia and compared to Matrigel, has been shown to upregulate EMT of PDAC cells and
increase invasiveness of glioblastoma spheroids [55,116].
In the present work, tumor-sphere and surrounding matrix fibril density were varied
independently to optimize the matrix biophysical properties which yield the most invasion of
PDAC cells in 5 days. For this optimization, Panc-1 cells were selected since they showed the
greatest invasive potential compared to other PDAC lines in preliminary experiments (data not
shown). The two different fibril densities applied in the present study correlated to matrix
stiffness values of 200 and 500 Pa. As shown in Figure 3-2, increasing the fibril density
(stiffness) of the surrounding tissue compartment from 200Pa to 500Pa drastically inhibited
tumor cell invasiveness. However, increasing the fibril density (stiffness) of the tumor sphere
only caused a slight decrease. More specifically, a cumulative distribution plot of invading cells,
suggested that increasing the surrounding collagen fibril density decreased both the number of
cells invading and the distance which they invade, while increasing the collagen fibril density of
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the tumor sphere only decreased the number of cells invading (Figure 3-2Bi). Further
quantification and statistical analysis revealed that the number of invading cells was indeed
highest when both the surroundings and sphere were of low fibril density (200 Pa; Figure
3-2Bii). Interestingly, for maximum invasion distance, the only difference that was statistically
significant was for increasing the surrounding fibril density of the denser (500 Pa) spheres
(Figure 3-2Biii). Altogether based on these results, it was established that low density (200 Pa)
Oligomer for both the sphere and the surroundings supported the greatest dynamic range of
invasion within the given experimental time span (5 days) and that these conditions would be
used for subsequent drug screening experiments.
3.3.3 3D metastasis model can support and distinguish various modes of tumor invasion
which are dependent on initial cell phenotype
Tumor invasion in-vivo is a dynamic and plastic process in which cells use a variety of
invasion strategies which depend on their genotype and phenotype, as well as the
microenvironment in which they are invading [112,117]. While mechanisms that regulate these
different modes of invasion are not fully understood, they are thought to rely on cellular
characteristics such as cellular contractility, integrin expression, matrix metalloproteinase
(MMP) expression, and EMT phenotype, as well as microenvironmental features including ECM
composition and microstructure, soluble factor signaling, and stromal cell interactions [118,119].
Interestingly, most human pathology studies have indicated that collective invasion of tumor
buds or strands is the most common form of invasion, but both in-vivo and in-vitro tumor models
have observed single-cell migration modes, including mesenchymal and amoeboid invasion, in
addition to collective invasion [120,121]. Because of these intricacies, it is important for in-vitro
models to be able to distinguish various tumor invasion modes known to occur in vivo.
To verify that this 3D HT-HC metastasis model supports different invasive phenotypes,
two PDAC cell lines, Panc-1 and BxPC-3, were chosen since based on published literature they
have different invasive and phenotypic profiles. Panc-1 was derived from a poorly differentiated
tumor with known metastases and is traditionally classified as mesenchymal, while BxPC-3 was
derived from a moderately differentiated tumor with no observed metastases and is classified as
epithelial [122]. Based on other published work, Panc-1 is also more contractile and
mechanosensitive in vitro and is more metastatic in vivo compared to BxPC-3 [123,124].
Consistent with expectations based on these established cells, Panc-1 exclusively invaded as
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Figure 3-3 Both extent and mode of 3D invasion depend on initial cell phenotype.
Tumor spheres prepared with 200 and 500 Pa oligomeric collagen were seeded with 1x10 7 cells/mL (Panc-1 and
BxPC-3) and embedded within surrounding oligomeric matrices of 200 Pa oligomeric collagen and cultured for
5 days. (A) Actin (green) and nuclear (blue) staining was performed to visualize and quantify invasion. Scale
bars = 100 μm (B) Quantified 3D tumor cell invasion represented with (i) a representative cumulative
distribution plot, (ii) average number of invading cells, and (iii) maximum invasion distance. (bars represent
mean ± std. dev., N=3, n=8-9; asterisks denote statistically different groups p<0.05)

single cells, while BxPC-3 demonstrated collective-cell invasion in addition to some single-cell
invasion (Figure 3-3A). Further, the morphology of invading Panc-1 cells were more spindleshaped typical of mesenchymal invasion and those cells of BxPC-3 which were single cells
appeared more rounded, indicating an amoeboid-like invasion. Upon quantification it was clear
that significantly more BxPC-3 cells invaded than Panc-1, and although there was a slight
difference in max invasion distance between the cell types, it was not statistically significant
(Figure 3-3B). Interestingly, increased tumor matrix stiffness significantly hindered BxPC-3
invasive capacity but did not decrease Panc-1 invasiveness. This decrease in BxPC-3
invasiveness with increased fibril density is consistent with the modes of invasion observed,
namely that dense ECM poses a more difficult barrier for collective invasion and amoeboid
invasion (MMP-independent mode of invasion). Further, the mesenchymal invasion observed in
Panc-1 has been observed in a genetically engineered mouse model with the same genetic
mutations (p53 and KRAS) [125], whereas the collective invasion of BxPC-3 is reminiscent of
human PDAC histopathology [120].
To further assess these different modes of invasion, immunostaining was performed on
samples from the low stiffness condition. For Panc-1, the more mesenchymal line, there
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appeared to be regions of E-cadherin staining in the center of sphere while vimentin was
expressed throughout. Invading Panc-1 cells showed prominent vimentin with very distinct
spindle-shaped morphology, again indicating mesenchymal cell invasion (Figure 3-4A). On the
other hand, the majority of BxPC-3 cells, even some of those invading, expressed E-cadherin
(Figure 3-4B). Minor vimentin expression was observed in the center of BxPC-3 spheres, but
was more prominently expressed in those cells which were invading. Interestingly, most
invading BxPC-3 cells expressed both E-cadherin and vimentin, especially those invading as
single cells or the cells on the periphery of groups of invading cells. Further the collective
invasion of BxPC-3 can be more clearly seen in these images, as budding protrusions of Ecadherin-positive cells are being led by vimentin-expressing “leader cells.” Overall, these results
verify and validate that our 3D metastasis model can distinguish pathophysiologically relevant
modes of tumor cell invasion [120,125].
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Figure 3-4 EMT status of invading cells depends on initial cell phenotype.
Tumor spheres prepared with 200 Pa oligomeric collagen were seeded with 1x10 7 cells/mL and embedded
within surrounding oligomeric matrices of 200 Pa oligomeric collagen and cultured for 5 days. After fixation,
constructs containing (A) Panc-1 and (B) BxPC-3 were frozen, cyrosectioned and stained for vimentin (red) and
E-cadherin (yellow); nuclei were counterstained with Hoechst 33342 (blue). Images represent maximum
projections of 20 μm confocal z-stacks; scale bar = 50 μm
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3.3.4 PDAC heterogeneity and desmoplasia can be more accurately recreated with lowpassage patient PDAC cells and CAFs
While immortalized cell lines serve as an important tool in cancer research and drug
development, it is thought that translating to non-immortalized, low-passage patient derived lines
better recreates tumor heterogeneity and preserves in-vivo phenotypes [22]. Additionally, CAFs
represent an important component of tumor heterogeneity and desmoplasia and have been shown
guide tumor invasion and modulate ECM remodeling that promotes metastasis [38,126,127]. To
verify that our 3D HT-HC metastasis model is compatible with these cell populations, two lowpassage patient-derived PDAC cell lines and a CAF line were incorporated into embedded tumor
spheres. One of the PDAC lines was derived from a primary tumor (10.05) and the other from a
metastatic lesion (Pa03C), and neither of these lines have been immortalized to better preserve
their in-vivo phenotype [128]. Interesting, compared to the immortalized cells used above (Panc1 and BxPC-3) these patient-derived cells do not appear very invasive by themselves but grow as
tight clusters within the sphere, though Pa03C does some minor single cell invasion (Figure
3-5A). When CAFs were added to the sphere, however, the CAFs invade into the surroundings
and significantly increase the invasiveness of the tumor cells (Figure 3-5B). Further, it appears

10.05

Pa03C
Pa03C + CAFs

B

10.05 + CAFs

A

Figure 3-5 CAFs increase invasiveness of patient-derived tumor cells.
Tumor spheres prepared with 200 Pa oligomeric collagen were seeded with 1x107 cells/mL, embedded within
200 Pa oligomeric collagen, and cultured for 4 days. Spheres contained (A) 10.05 or (B) Pa03C cells without
and with CAFs (1:1 tumor:CAF ratio). Images represent nine fields of view, each of which is a maximum
projection of a 400 μm confocal z-stack. Red = tumor cells (TdTomato Red) and green = CAFs (Green
Fluorescent Protein). Scale bars = 200 μm
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that the CAFs more drastically effect 10.05 cells compared to Pa03C, which is consistent to the
behavior of these cells in xenograft models (data not shown).
To more clearly define how these stromal cells guide tumor invasion and define the EMT
status of tumor cells, immunostaining of in-vitro tissue sections was performed. As expected,
tumor cells within the sphere have prominent E-cadherin and the CAFs stain strongly for
vimentin (Figure 3-6). Very little overlap was seen between the TdTomato Red channel and the
vimentin stain, indicating that vimentin expression was not prominent in cancer cells, even in
those invading. Interesting it also appears that CAFs are physically guiding tumor cell invasion
as groups of tumor cells can be seen in close proximity to CAFs as they invade into the
surroundings. It is also notable that this interaction appears to be independent of EMT-status
since tumor cells still appear to be expressing E-cadherin as they invade. Overall, these results
confirm the compatibility of our model with more relevant cell populations and validate that
CAFs play an important role in PDAC tumor invasion in our model, as is thought to be the case
in vivo [127] .
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Figure 3-6 CAFs physically guide tumor cell invasion independent of EMT status.
Tumor spheres prepared with 200 Pa oligomeric collagen were seeded with 1x10 7 cells/mL, embedded within
200 Pa oligomeric collagen, and cultured for 4 days. Spheres contained (A) 10.05+CAFs or (B) Pa03C+CAFs
(1:1 tumor:CAF ratio). Images represent cryosectioned samples which were stained for E-cadherin and
vimentin. Each image is a maximum projection of a 20 μm confocal z-stack. Final panel represents a 3x zoom of
the boxed region in the overlay panel. Arrowheads denote direct interaction between tumor cells and CAFs.
Yellow = E-cadherin, Blue = vimentin, Red = tumor cells (TdTomato Red) and green = CAFs (Green
Fluorescent Protein); Scale bars = 50 μm.
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3.3.5 PDAC metastasis model is amenable to HT-HC drug screening
Designing 3D in-vitro models which balance the need for pathophysiologic relevance
with the ability to scale-up to high-throughput systems, is one of the many challenges in
developing translatable preclinical models [23]. Further, very few, if any, 3D in-vitro models
apply multiplex, optical assays which can be visualized with automated imaging platforms.
Therefore, to showcase the potential of this model as a tool for HT-HC drug screening, a proof of
concept drug screen was performed to verify model reproducibly and to validate the ability to
image this model using a high-throughput, automated microscope. Panc-1 and BxPC-3 cells were
treated with a 10-point dilution of gemcitabine with STS and DMSO serving as positive and
negative controls, respectively. Additionally, a multiplex assay was developed which used
Hoechst 33342 to measure total cell numbers and invasion, Click-iT EdU to stain cells
undergoing DNA synthesis (proliferation), and MitoTracker Red to evaluate metabolic activity.
Automated confocal imaging was performed using an Opera Phenix High-Content Screening
System; representative images of a single row of a well plate are shown in Figure 3-7A. These
images demonstrate the reproducibility of model creation, showcasing its potential for highthroughput imaging and high-content analysis. Additionally, they reveal a sharp drop-off in cells’
proliferative capacity when exposed to increasing doses of gemcitabine but only a gradual
decrease in metabolic activity. Subsequent image analysis using Perkin Elmer’s Harmony
software enabled quantification of measurable outcomes for proliferation, metabolic activity, and
invasion from which we generated dose response curves (Figure 3-7B) and associated IC50 and
Emax values (Figure 3-7C). For both Panc-1 and BxPc-3, the IC50 for metabolic activity was
significantly higher than the IC50 for proliferative capacity and invasion. Additionally, the
metabolic activity IC50 value was significantly higher for BxPC-3 compared to that of Panc-1.
For Emax, the value for proliferative capacity was lowest for both cell lines; for Panc-1, it was
significantly lower than the Emax of metabolic activity while for BxPC-3 it was significantly
lower than the Emax of invasion. In summary, these results validate the ability of this model to
translate to HT-HC screening and demonstrate the rich datasets that can be created using
multiplex assays such as the one used here.
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Figure 3-7 Proof of concept drug screen validates translation potential of HT-HC metastasis model
(A) Tumor spheres prepared with 200 Pa oligomeric collagen seeded with 1x107 cells/mL (Panc-1) were
embedded within surrounding matrices of oligomeric collagen (200 Pa) and treated with serial dilutions of
gemcitabine, 20 μM STS (kill control), and 1% DMSO (vehicle control) for four days. Images were obtained
using an Opera Phenix and represent a maximum projection of a 500 μm z-stack. (i) overlay of all channels (ii)
Click-it Edu 488 staining proliferating cells, (iii) Mitotracker Red staining active mitochondria, and (iv) Hoechst
33342 staining nuclei. (B) Representative dose response curves for (i) proliferative capacity, (ii) metabolic
activity, and (iii) invasion for both Panc-1 and BxPc-3. (C) (i) IC50 and (ii) Emax values were calculated from
dose response curves from independent experiments (N=3) and compared Tukey-adjusted multiple comparisons.
Letters over bars (mean ± SD) denote statistically different groups (p<0.05).

Discussion
Since the efficiency of molecular target-based screening—the current industry standard
for drug development—has recently come into question, phenotypic screening approaches are
now being explored with renewed interest in order to improve the efficiency of drug
development and reduce clinical trial attrition rates [7,9]. Because of this, the need for models
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which more accurately recreate specific disease phenotypes is more prevalent than ever [10,22].
Metastatic phenotypes are especially in need of more predictive preclinical models since the
metastatic process is a complex series of steps with incompletely understood mechanisms,
making target-based screening especially difficult [25,129]. Additionally, there a few models
which are able to balance complexity and accurate recreation of metastatic phenotypes with
high-throughput capacity [23]. Table 3-1 compares a few of the most common tumor invasion
models with specific regard to criteria developed from several review articles about
pathophysiologic relevance and practical considerations [10,22–24].
Scratch or exclusion zone assays and transwell invasion models both involve seeding
tumor cells on a planar surface and measuring the migration or invasion of cells in constrained
non-physiologically relevant geometries. Although these models are amenable to more highthroughput analysis and are fairly reproducible, they do not accurately recreate the tumor
interstitium and they offer very little user control to enable customization and standardization
[29,108]. Further, while ECM coatings of Matrigel, type I collagen or fibronectin can be applied
to these surfaces, these thin layers of ECM proteins do not recreate the complex 3D fibril matrix
through which cells invade in vivo [99,112]. 3D spheroid invasion assays are often considered to
be a more relevant tumor invasion model since the 3D architecture of spheroids themselves as
well as their embedment within 3D matrices is thought to more accurately recreate the tumor
microenvironment [108]. Unfortunately, however spheroid-based models do not meet several of
important practical considerations (Table 3-1). Since spheroids rely on the self-aggregation of
cells they are difficult to customize and standardize, their creation is time-consuming, and they
are often cited as having reproducibility issues [21]. While some work has been done to develop
more reproducible spheroids or larger tumor spheres [130–132], there remains solution to
reproducibly embed spheroids or spheres within the wells of standard well plates.
Thus, the goal of this work was to develop and validate a novel HT-HC metastasis model
that was pathophysiologically relevant as well as practical to implement and feasible to translate
to HT-HC drug screening. This model builds on previous work using type I collagen Oligomer to
create cell-dense tissue spheres embedded within a 3D collagen-fibril matrix to create adjacent
and independently tunable tissue compartments [114]. The use of Oligomer which is a
standardized ECM material with a broad range of tunability [18], along with this unique model
design provide a high level of user. This user control provides the ability to customize and
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Table 3-1 Comparison of common in-vitro metastasis models
Criteria for relevant and translatable in
vitro models

Scratch or
exclusion zone

Transwell
invasion

3D spheroid
invasion

3D metastasis
model

2D

Semi-3D

Embedded 3D

Embedded 3D

Thin layer of
Collagen fibril
Matrigel or fibril
matrix
collagen

Collagen fibril
matrix

model geometry

Pathophysiologic Relevance

Relevance of
disease model

ECM
microstructure

None usually
present

Can incorporate
stromal cell
populations?

No

Yes

Yes

Yes

No

No

Yes

Yes

Artificial

Artificial

Natural

Natural

relevant
metastatic
relevance of stimuli phenotypes?
and phenotype
Is stimuli natural
or artificial?
Metastasis
Relation between
assay and clinical
outcomes

Tumor growth
and progression

Translational Considerations

Model creation
takes < 1 hr
uses minimal
Fast, simple,
specialized
reproducible model equipment
creation
reproducible
creation of
model
Uses standard
well-plates
amenable to scale- Able to image
up for high
with automated
throughput
systems
screening
quantify relevant
phenotypic
outcomes?
User control of
Ability for
tumor properties
customization and
User control of
standardization
surroundings

Poor: 2D
Poor: Migration Good: Invasion Good: Invasion
migration/wound through artificial through 3D fibril through 3D fibril
closure
confined pores
matrix
matrix

None

None

None

Good: Direct
measures of
proliferation and
metabolic
activity

+

+

-

+

+

+

-

+

+

+

-

+

+

+

-

+

+

-

-

+

-

-

-

+

Minor

Minor

Minor

High

none

Minor

Moderate

High
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optimize both cellular and ECM properties to apply this model to other cancer types and
diseases, and enables standardization of model setup to translate it as screening platform.
Further, the development and use of a custom fabrication platform to facilitate model creation,
provides rapid model setup and reproducible sphere creation and embedment—two necessary
characteristics for high-throughput use. Finally, the present work has validated that this model
can distinguish various phenotype-dependent modes of invasion and is able to translate to HTHC imaging and analysis.
To our knowledge, there are few published examples of tumor invasion models which
achieve a balance between relevance and practicality, as the HT-HC metastasis model does. One
such model with similar goals to ours did not use standard well plates but involved
microfabrication of a custom device to create and subsequently embed spheroids [133]. Since
this model still relied on the self-aggregation of cells to form spheroids, model creation appeared
to be a complicated, time-consuming process (3-4 days) which would not be amenable to
automation and it does not appear that their custom device would interface with standard
automated imaging systems. Another model followed a similar approach to the present work, but
instead of embedding preformed spheres within a 3D matrix, it involved creating cell-dense
collagen spheres in hemispherical pits in the bottom of the wells of a customized 96-well plate
followed by overlaying the spheres with collagen [134]. While this strategy did allow them to
create a cell-dense sphere in the center of each well, since it was in contact with the bottom of
the well and they did not validate that cells were invading into the overlaying 3D matrix, it is
likely that most of the “invasion” that they observed was really migration on the bottom surface
of the well plate since cells will preferentially migrate along paths of least resistance [135].
Additionally, because they were using a monomeric collagen formulation and were not fully
embedding their spheres, they had to exogenously crosslink the matrix with dialdehyde dextran
to prevent sphere contraction. Based on this, we believe that our custom fabrication platform is
the first of its kind that allows for the rapid, reproducible creation of tumor spheres and their
subsequent, full 3D embedment in the wells of a standard 96-well plate.
The HT-HC metastasis model developed in this work not only provides a solution for
some of the practical considerations in Table 1 but it also provides a pathophysiologically
relevant microenvironment which can distinguish various modes of tumor invasion based on cell
phenotype. The branched fibril architecture of the Oligomer matrices used here accurately
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recreates the interstitial tissue laid down in desmoplasia, creating a relevant barrier to PDAC cell
invasion [32]. The trend of decreased invasiveness with increased surrounding stiffness
correlates with other 3D embedment models and genetically engineered mouse models, but is
opposite of durotaxis, the preferential migration of cells in 2D from soft to stiff substrates
[53,54,78,79,136]. As with other phenotypic behaviors, 3D fibril matrices, in vitro and in vivo,
provide different geometric and spatial constraints to cell invasion and migration than 2D
culture, and therefore often lead to different trends [53,99]. Further, in the present work, the
more mesenchymal PDAC cells, Panc-1, exclusively invaded as elongated, spindle-shaped single
cells with prominent vimentin expression, all indicating a mesenchymal mode of invasion.
Notably, this mode of invasion has been observed with intravital imaging of a genetically
engineered mouse model of PDAC with the same mutations as Panc-1 (KRAS and p53) [125].
On the other hand, the epithelial line, BxPC-3, demonstrated both single-cell, amoeboid-like
invasion and collective invasion with some partial EMT in subpopulations of invading cells.
These observations are reminiscent of clinical human tumor samples, in which only
subpopulations of cells are noted as having undergone EMT and collective invasion and tumor
budding have been noted to be more prominent that single cell invasion [104,120]. Overall, these
results confirm this model’s capacity to support and distinguish relevant invasive phenotypes by
accurately recreating the 3D fibril architecture through which cells invade in vivo.
To both increase and further demonstrate the pathophysiologic relevance of this
metastasis model, low-passage patient derived lines and CAFs were incorporated in the
embedded tumor spheres. From this, CAFs were found to significantly enhance, and even be
necessary for invasion of these PDAC cells in our model. These results align with how invasion
is thought to occur in PDAC in vivo, with CAFs playing a prominent role [137,127].
Specifically, others have shown, both in vivo and in vitro, that in addition to soluble factor
signaling, CAFs physically interact with tumor cells too guide their invasion. [137,138]. Though
this phenomenon was not explored more fully in the present work, it appeared that CAFs and
tumor cells are indeed physically interacting as they invade (Figure 3-6). Further work would be
needed to fully explore these interactions and different modes of invasion, but these results
validate this model’s ability to support relevant phenotype-dependent modes of invasion and
demonstrate the potential of this model for systematic studies to further elucidate the mechanism
at play in the various tumor invasion strategies.
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Finally, and most importantly, we validated this model’s amenability to HT-HC
screening by performing a proof of concept drug screen with an automated imaging system and
multiparametric analysis. The ability to image this model using an automated system such as the
Opera Phenix High Content Screening System (Perkin Elmer) verifies our design’s ability to
reproducibly create and embed tumor spheres within the well of a standard well plate. While
others have created microfabricated platforms and custom-well plates for similar purposes
[133,134,139], our design interfaces with standard well plates making it easy to scale-up and
translate to other labs. Further, unlike traditional cytotoxicity assays which only use metabolic
activity to measure cell viability, quantifying multiple phenotypic parameters as we have done
here, opens the door for advanced mechanistic understanding of how drugs affect tumor cells. In
this proof of concept screen, gemcitabine appears to be effective at hindering proliferation but is
not able to fully kill cells or stop invasion. Additionally, since proliferative capacity and invasion
have similar IC50 values this may suggest that a significant portion of invasion is driven by
proliferation however since they have different Emax values, there are some invading cells not
proliferating which are unaffected by gemcitabine. These observations would need to be
validated with future mechanistic studies, but these results showcase both the potential of this
model to be used in high-throughput, high-content screening and the rich data that can be
generated using multiplex assays such as the one used here. In the future, these in-vitro measures
of proliferative capacity, metabolic activity, and invasion can be correlated with in vivo or
clinical evaluations of tumor growth, metabolic tracers, and metastatic spread to validate that this
model can serve as a predictive tool of in vivo drug response and clinical outcomes.

Conclusion
With the ever-rising demand for more pathophysiologically relevant tumor models, it is
important to also consider how these advanced models will translate and integrate with existing
workflows in the pharmaceutical industry. In this work, we aimed to develop a model system
which accurately recreated specific features of the human disease while maintaining the ability to
quantify relevant outcomes using high-throughput imaging systems. Specifically, our novel 3D
HT-HC metastasis model recreates PDAC desmoplasia and is able to quantify true 3D invasion
and distinguish various invasion strategies. Additionally, it allows for user customization and
standardization, model creation is simple, rapid and reproducible, and finally, it is amenable to

55
automated imaging and analysis to enable high-throughput, high content screening. Further
validation of this model that remains to be completed is screening with compounds of various
mechanisms of action to validate our multiplex assay and validation of the model’s predictive
power by comparison to in vivo models. Once complete, we believe that this 3D metastasis
model has great potential to serve as powerful tool for preclinical drug development to identify
new therapies for PDAC and decrease the high attrition rates of cancer clinical trials.
In addition to this model’s potential as a HT-HC drug screening platform, there many
other future applications for which this model can be used. Because of its high degree of user
customization over both the composition and biophysical properties of both tissue compartments,
this metastasis model would be a powerful tool for systematic study of mechanobiology-related
mechanisms which are thought to be highly important in tumor invasion and metastasis [35,140].
Further, because of the size and robust nature of the embedded spheres, this model could also fill
a gap by being used as an in-vitro platform to test radiation or ablative therapies since traditional
spheroids are not large enough to do this [23]. Finally, this phenotypic model of metastasis could
be used as a high-content “culture and sensitivity” screen for personalized medicine. Using this
model to perform medium throughput screening of potential therapies on tumor cells derived
from a patient biopsy could provide phenotypic outcomes (e.g. invasion, metabolic activity, and
proliferation) to compliment the genotyping, already performed on these samples. In this way,
physicians would be able to integrate genotypic and phenotypic information to decide on the best
course of therapy for a given patient. In summary, the model developed in this work has great
potential for HT-HC drug development, as well as mechanobiology and personalized medicine.
.
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4. FURTHER MODEL VALIDATION, FUTURE WORK AND
CONCLUSIONS

Introduction
The medical device development process has served as the framework for the model
development work performed in this thesis. This process involves the following steps:
understanding user needs, defining design inputs, iterative design and testing, design verification,
and finally design validation. Within this context, Chapter 1 introduced some of the
shortcomings in the anti-cancer drug development process and defined important user needs and
design criteria for preclinical phenotypic screening models. Chapter 2 more specifically defined
important 3D in vitro model design parameters, namely 3D collagen fibril architecture and model
geometry, and established oligomeric type I collagen as a powerful tool for model development.
Finally, Chapter 3 described the development of a novel 3D high-throughput, high content (HTHC) metastasis model which accurately recreates PDAC desmoplasia and is able to scale-up for
HT-HC drug development. Additionally, several aspects of design verification and validation
were performed in Chapter 3. Design verification included demonstrating this model’s capacity
for rapid, reproducible experimental set-up, its ability to quantify 3D invasion, and its potential
for customization and standardization. Validation in Chapter 3 included confirming this model’s
ability to distinguish various metastatic phenotypes, its compatibility with relevant cell
populations to recreate PDAC heterogeneity and desmoplasia, and its ability to translate to HTHC drug screening. To more fully validate this model, the following sections outline some
proposed next steps and present preliminary data for the proposed validation work. Finally, the
future potential of this work and overall conclusions from this thesis are discussed.

Proposed Next Steps of Model Validation
Since we have verified several aspects of our design and validated that our 3D metastasis
model is capable of translating to HT-HC drug discovery (Chapter 3), the next steps of
development includes validation of pathophysiologic relevance and predictive power. It is often
assumed that 3D in-vitro models are more pathophysiologically relevant and more predictive of
in-vivo behavior than traditional 2D culture, however these assumptions are rarely validated [22–
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24]. To fill this gap, proposed model validation includes the following two key steps. First, to
validate that the 3D HT-HC metastasis model accurately recreates important aspects of human
PDAC, histological and immunohistological comparisons to xenograft and human tumor samples
will be performed. Second, comparative drug treatment studies with gemcitabine and a novel
drug target will be performed to validate if outcomes from this in-vitro model align with
outcomes from an in-vivo model.
This validation work will be performed collaboratively with the labs of Melissa Fishel
and Mark Kelley at Indiana University School of Medicine. The Fishel lab is focused on
identification and preclinical validation of novel anti-cancer therapies using both in-vivo and 3D
in-vitro tumor models, while Kelley is focused on translating novel therapies to the clinic. This
collaborative effort has already begun as they provided the low-passage patient derived lines and
CAFs used in Chapter 3. For the validation of our model we will also be focusing on one of the
novel drug targets in their lab—reduction-oxidation factor-1 (Ref-1). Ref-1 is an important redox
regulator of specific transcription factors known to be important in tumor progression and
metastasis, namely STAT3, HIF-1α, and NF-кB [141]. Additionally, they have shown that this
protein is highly upregulated in human PDAC tumors (unpublished data) and has great potential
as a clinical drug target. In fact, one of their potential therapies that targets Ref-1, APX3330, has
been approved by the FDA as an Investigation New Drug (IND) and will be starting in clinical
trials in early 2018. This protein (Ref-1) and novel therapy (APX3330) will serve as a specific
application for our final model validation. The following preliminary work has already begun
and is briefly described below: i) initial attempts at histological evaluation of our in vitro model,
ii) immunostaining to validate relevant protein expression patterns, and iii) a pilot drug screen.
4.2.1 Histological evaluation
Unlike many 3D in-vitro models such as those based on spheroids and Matrigel which are
difficult to post-process after fixation, the HT-HC metastasis model supports in-situ
crysectioning, as demonstrated with immunostaining results from Chapter 3. To provide a
clinically translatable and comparable outcome, initial work has been performed with traditional
hematoxylin and eosin (H&E) staining. However, since the collagen density in this model is low
compared to in-vivo tissue, eosin was not well retained (data not shown). To provide better
staining of the cyrosectioned samples, another common histological stain, Sirius Red, was used;
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this dye stains type I collagen fibers and is commonly used to evaluate collagen networks in
tissues [142]. Briefly, after fixation, freezing and crysoectioning (60 μm sections), slides were
stained with Sirius Red (70 mM in 1% acetic acid) and Ricca Triple Strength hematoxylin. Slides
were rinsed with increasing concentrations of ethanol, fully dehydrated with xylene, and
mounted with Paramount.
Preliminary images of Sirius Red and hematoxylin stained samples are summarized in
Figure 4-1. These images show that without CAFs present, 10.05 cells grew as tightly grouped
structures reminiscent of neoplastic ducts while Pa03C tended to remain more as single cells
with only some clustering. For both cell types, there was essentially no invasion into the
surrounding tissue when CAFs are not present. However, when CAFs were added to the sphere,
they appear to guide invasion of the tumor cells into the surrounding environment. Additionally,
they appear to drastically increase proliferation of tumor cells since the center of these sphere
appear so dense that it becomes difficult to distinguish individual cells or cell clusters. These two
outcomes correlate with the role that CAFs are said to play in vivo, where they increase tumor
proliferation and metastasis [127,143]. Additionally, these images represent the potential of our
model to be histologically analyzed, though further optimization of the sectioning and staining

Figure 4-1 Preliminary images of in-vitro metastasis model histology.
Tumor spheres (200 Pa Oligomer) composed of patient derived cell lines with or without CAFs were embedded
within 200 Pa Oligomer and cultured for 4 days. Constructs were fixed, frozen, and crysectioned followed by
staining with Sirius and hematoxylin. Images were taken in the center and at the edge of each sphere.
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technique is still needed to obtain higher quality images for comparison to in-vivo samples.
Paraffin embedment and sectioning will be also explored to achieve better resolution and more
comparable images to those of in-vivo tissue sections. Once complete, the comparison of the HTHC metastasis model to human tumor samples and xenograft tumor samples will validate that
this model accurately recreates PDAC histoarchitecture.
4.2.2 Proposed immunofluorescent comparisons
Another step of model validation is confirming the protein expression and distribution
within this in-vitro model correlates with what is known about PDAC tumors in vivo. The two
key proteins that have been evaluated to date are Ref-1 and Ki-67. As mentioned above Ref-1 is
an important regulator of transcription factor activity and is upregulated in human PDAC [141].
Ki-67 is a commonly-used clinical biomarker of cell proliferation as it is expressed in all cells
which are actively cycling but not expressed in quiescent cells [144]. Additionally, increased Ki67 staining in clinical samples has been correlated with poor prognosis in PDAC [145]. By
staining and visualizing the distribution of these two proteins, comparisons to published
literature about human PDAC tumors can be made. Immunostaining was performed as described
previously (Chapter 3). Cryosectioned samples were permeabilized with 0.1% Triton X-100 and
blocked with 1% bovine serum albumin before overnight incubation at 4 °C with primary rabbit
antibodies for Ref-1 and Ki-67. Anti-rabbit Alexa Fluor 633 secondary antibody was then
applied followed by nuclear counterstaining with Hoechst 33342.
Preliminary images from spheres composed of 10.05 cells without CAFs are shown in
Figure 4-2. From these images, it appears that Ref-1 is expressed in almost all tumor cells
throughout the tumor sphere, regardless of location. This is consistent with findings from the
Fishel lab that Ref-1 is prominent throughout human PDAC tumors (unpublished data). Ki-67,
on the other hand, appears to be more prominent in cells around the edges of the sphere than in
the center which correlates to the different biological zones that are thought to exist in tumors in
vivo, namely a proliferative rim and a quiescent or necrotic core [110]. To further validate and
extend these conclusions, immunostaining of both low-passage patient derived PDAC cells
(10.05 and Pa03C) with and without CAFs will be performed. Additionally, comparison to
immunohistochemistry of human tumors samples will be performed to validate
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Figure 4-2 Preliminary immunostaining images.
Tumor spheres (200 Pa Oligomer) composed of 10.05 patient derived cell lines were embedded within 200 Pa
Oligomer and cultured for 4 days. Constructs were fixed, frozen, and crysectioned followed by immunostaining
for (A) Ref-1 and (B) Ki-67. Images represent maximum projections of 20 μm confocal z-stacks. Whole sphere
images represent 16 fields of view stitched together. (Green = (A) Ref-1, (B) Ki-67; Blue = nuclei; Red =
TdTomato Red)

pathophysiologically relevant expression profiles. Other protein biomarkers of interest that may
be included in these comparisons include markers for ECM proteins (e.g. hyaluronic acid,
fibronectin), hypoxia (e.g. carbonic anhydrase-9), and cancer stem cells (e.g. CD24, CD44)
[76,128,146]. By performing this proposed analysis and comparison of protein expression
patterns, the pathophysiologic relevance of our 3D HT-HC metastasis model will be validated.
4.2.3 Pilot drug screen for comparative drug treatment studies
Finally, validation of this model’s predictive power should be performed to highlight its
potential to replace or reduce the use of animal models in preclinical drug development. To
accomplish this, it is proposed that in-vitro to in-vivo comparative drug treatment studies with
gemcitabine and APX3330 be performed. Toward this end, a pilot drug screen comparing
gemcitabine and APX3330 has been performed with the low-passage patient cells and CAFs.
Briefly, tumor spheres with 10.05 +CAFs and Pa03C+CAFs were created and emdedded using
the fabrication platform, as described previously (Chapter 3). After 24 hours and every 24 hours
thereafter, drug treatments of both drugs were applied as a standard 10-point dilution starting
with a starting concentration of 200 μM. Experiments were fixed after 4 days (96 hour total
experiment time), imaged on the Opera Phenix High-Content Screening System, and analyzed
using the accompanying Harmony software. Since the low passage-patient derived lines and
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CAFs stably express TdTomato Red and green fluorescent protein, respectively, no further
staining was performed for this proof of concept screen and the fluorescent intensity of these two
markers were used to assess viability [128]. To quantify the fluorescent intensity of each
channel, first, a region of interest was created by thresholding each respective channel to exclude
background, followed by summing the intensity within the created region. The value for each
well was then normalized using the following equation: 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 =
(I𝑛 − I𝑆𝑇𝑆 )⁄(I𝐷𝑀𝑆𝑂 − 𝐼𝑆𝑇𝑆 ). In represents the value of the nth dilution. ISTS and IDMSO represent
values from kill control and vehicle control, respectively.
Figure 4-3 summarizes the data obtained from this pilot drug screen. Based on the
images, there appears to be little discernable change across the dilution off either drug except for
the highest concentration of APX3330 which appears to inhibit invasion and to have slightly
lower signal intensity. Clearly none of the drug dilutions are achieving the same level of kill as
the STS control, in which there is only slight fluorescence remaining from the tumor cells
(TdTomato red). Quantification of these images provides further insight to the cellular response
to these two drugs (Figure 4-3B,C). Notably, for each set of conditions there is a slight
downward trend as drug concentration increases (right to left), though only the high
concentration of APX3330 on Pa03C+CAFs reached a similar fluorescent intensity level to the
STS kill control (relative fluorescence of 0). Otherwise, relative fluorescence of tumor cells
remained above approximately 0.2 or 20% of the DMSO control. For CAFs, the relative
fluorescence remained above 0.3, with most values being above 0.5, indicating that the drugs did
not significantly kill the CAFs. While it is difficult to make more significant conclusions from
this preliminary data we hypothesize that since this model accurately recreates PDAC
desmoplasia and heterogeneity, we will also recapitulate this cancer’s resistance to gemcitabine
treatment [147]. From this initial data it does appear to be the case since even when exposed to
200 μM gemcitabine, the relative fluorescence of Pa03C and 10.05 cells remains quite high (0.23
and 0.45, respectively). While this remains to be validated with further experiments, this
conclusions would be significant since a recent review claimed that no in vitro PDAC models to
date have truly recreated PDAC’s clinical resistance to therapy [24].
Future work for this aspect of model validation includes further refinement of imaging
and analysis techniques, as well as in-vitro to in-vivo comparison studies. While including two
distinct cell populations (tumor cells and CAFs) does increase the relevance of this model, it also
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makes quantitative analysis more challenging. The use of fluorescently-labeled cells, as done
here aids in this somewhat, but limits the analysis to measures simply based on the fluorescent
intensity of these cells. To enable more high-content analysis, further refinement of imaging and
image analysis techniques will be explored, to at the very least include measures of viability and
invasion. Additionally, results from in-vitro drug dosing studies will be compared to analogous
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Figure 4-3 Pilot drug screen with APX3330 and gemcitabine.
Tumor spheres (200 Pa Oligomer) composed of patient derived cell lines with or without CAFs were embedded
within 200 Pa Oligomer and cultured for 4 days. Drugs dilutions (gemcitabine=GEM, APX3330=APX), as well
as 10 μM STS and 1% DMSO controls, were applied every day. (A) Images were obtained using Opera Phenix
High-Content Screening System and represent 4 fields of view, each of which is a maximum projection of a 500
μm z-stack; tumor cells = red (TdTomato Red), CAFs= green (Green Fluorescent Protein). For both (B)
gemcitabine and (C) APX3330 dosing, quantitative image analysis was performed to calculate the relative
fluorescent intensity of both tumor cells (red bars) and CAFs (green bars). (Note: In (A), black images in the 3rd,
5th, and 11th column represent wells in which 3D constructs were accidently aspirated during post-processing. In
(C) the missing data for these columns are noted with asterisks (*))
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in-vivo drug treatment experiments with xenograft mouse models using the same cells. By
performing these comparisons with the same cell populations, parallels will be drawn based on
cellular phenotype and the influence of CAFs in the two models, in addition to the potency and
efficacy of the two drugs tested. Specifically, in-vivo tumor growth and metastatic spread will be
compared to measures of viability and invasiveness in vitro. In summary, this proposed work has
potential to validate that the 3D HT-HC metastasis model developed in this work provides
similar outcomes to an in-vivo model, and therefore may be more predictive of clinical outcomes.

Future Work
In addition to the model validation described above, the model developed in this work
has potential for many future applications and studies. A few of these include automation of
experimental setup to enable truly high-throughput screening, mechanistic study of metastasis
mechanobiology, and translational for personalized medicine. These different applications are
briefly described in the following sections.
4.3.1 Automation and HT screening validation
To truly translate this HT-HC metastasis model as a drug screening platform,
collaborative efforts with drug discovery groups in academia or industry would be needed to
automate the experimental setup. Since the fabrication platform developed in this thesis is
already user friendly and was designed to interface with standard 96-well plates, it should be
straightforward to customize commercial liquid handling robots to facilitate automated model
setup. One of the major hurdles of this would be temperature regulation since the oligomeric
collagen would need to be kept cool (4 °C) before pipetting and then subsequently heated (37°C)
to polymerize. However, once this increase in throughput of model setup is achieve it would in
turn enable truly high-throughput screening in order to validate the high-content assay outcomes
by testing drugs of various mechanisms of action. Specifically, drugs that are known to inhibit
proliferation, metabolic activity and invasion could be tested to validate that each of the
outcomes of the high-content assay can be independently modulated. Additionally, positive and
negative reference compounds, (i.e. those which have gained FDA approval and those which
have failed in clinical trials due to lack of efficacy, respectively) could be used to further validate
the predictive power of this HT-HC metastasis model.
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4.3.2 Mechanistic studies
Mechanobiology is very important in metastasis since cells experience a diverse range of
physical properties as they invade through surrounding tissue, intravasate into the circulation,
and disseminate to distance sites in the body [35,105]. Even though the initial metastatic events
of EMT and invasion are widely studied, the mechanobiology underlying these processes is still
not fully elucidated. However, it is known that ECM microstructure and topography, as well as
the biophysical force balance between the cytoskeleton and the ECM are important in guiding
invasion [148]. Examples of this include the creation of “highways” for cancer invasion either as
microtracks in matrices in vitro and in vivo or the alignment of collagen fibers perpendicular to
the tumor boundary [38,135]. To more fully understand these processes, the high level of user
control offered by the HT-HC metastasis could be used to explore how changes in ECM
composition and microstructure influence tumor invasion. Specifically, the collagen
concentration and the ratio of collagen oligomers to monomers could be varied independently to
define how fibril density and interfibril branching influence invasion [57,58]. Additionally, since
the mechanobiology associated with when and why cells employ different modes of invasion is
also not fully understood, this customizable model could provide the opportunity to define
relationships between tumor invasion mode and ECM biophysical properties. More detailed
genomic and proteomic analysis could also be performed to elucidate mechanisms underlying
various invasive phenotypes within different matrix conditions. Altogether, because of the high
level of user control that this model offers it has great potential to serve as a useful tool for
mechanistic mechanobiology.
4.3.3 Personalized medicine
Finally, this HT-HC metastasis model also has potential for use in precision medicine—
the concept of tailoring treatment strategies to fit individual patient needs. Since cancer is one of
the main focuses of the National Institutes of Health Precision Medicine Initiative the National
Institute of Cancer (NCI) has developed several focused programs, one of which is to develop
novel laboratory models which can be used to further characterize patient tumors and provide
patient-specific predictions of treatment response [149]. Since the compatibility with patient
derived cells has already been validated, the HT-HC metastasis model developed in this thesis
could be used to characterize the phenotype and metastatic potential of patient tumor samples, as
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well as perform screening on potential therapies to further inform physicians on choosing the
best treatment approach for each individual patient. Next steps in this would be to obtain patient
samples either through clinical collaborations or the NCI’s Patient Derived Model Repository
and evaluate the metastatic potential, genotype, histopathology, and treatment response in vitro.
These in-vitro results could then be compared to the known clinical history, genetic profile and
histopathology report to establish correlations. Others have performed these types of
comparisons and predictions using ex-vivo cultured tumor tissue section and machine learning
algorithms, however these models did not recreate the 3D microenvironment of human tumors
and metastatic potential was not assessed [150]. Therefore, the HT-HC metastasis model could
fill a gap in precision medicine by providing a pathophysiologically relevant platform on which
treatment response and metastatic potential could simultaneously be evaluated to compliment
genotypic analysis in order to choose the best treatment strategy for cancer patients.

Conclusions
Overall this work represents the initial stages of model development for a novel 3D HTHC metastasis model with potential for phenotypic drug screening, mechanistic study, and
personalized medicine. Further, once the above described validation is complete, the 3D
metastasis model developed in this thesis will have overcome several key translational hurdles
and be one step closer to translation to preclinical use. Additionally, this work showcases some
important considerations when developing translatable in vitro models and hopefully will serve
as a catalyst for future model development. Results from this work have made it clear that ECM
composition and fibril microstructure are important factors to consider when developing 3D invitro models. While this may seem like an already established conclusion with prevalence of 3D
culture and mechanobiology work, the field’s reliance on Matrigel- and PEG-based tumor
models suggests that the importance of these factors is not fully realized by many. Additionally,
this work has highlighted the potential of standardized ECM materials such as Oligomer, that are
not only standardized to improve reproducibility but also accurately recreate natural fibril
architecture and are customizable over a wide range of biophysical properties. Using this unique
biomaterial, a novel 3D metastasis model was developed that overcame several shortcomings of
other commonly used models. Key verification and validation of this model included 1)
demonstrating its ability for customization and standardization, 2) its compatibility with relevant
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cell populations to recreate PDAC heterogeneity and desmoplasia, 3) its capacity to support
relevant invasive phenotypes, and 4) its ability to translate as a high-throughput, high-content
screening tool. While much work remains to further validate this model, development and
application of this 3D HT-HC metastasis model has great potential to improve the efficiency of
the development of anti-cancer therapies. Ultimately, by utilizing models which more faithfully
recreating human tumors such as the one developed in this thesis, the success rate of anti-cancer
clinical trials will be improved, leading to more effective therapies and better patient outcomes
for highly metastatic cancers like PDAC.
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APPENDIX

Chapter 3 Supplemental Information
Table S 1 – Comparison of gemcitabine IC50 values for PDAC lines in 2D
IC50 (nM)
Experimental Conditions
Cell Density
Duration
BxPC-3 Panc-1 MiaPaCa-2
Culture Medium
3
(hr)
(10 cells/well)
830
95
494
4
RPMI for all
72
RPMI for BxPC-3; DMEM
13.6
137
7.73
2
96
for Panc-1 & MiaPaCa-2
RPMI for all but MiaPaCa5,910
58,200
11,430
5
72
2

Assay

Reference

WST-1
Cell Titer
Glo

[151]

MTT

[153]

[152]

17.9

27

51

20

DMEM for all

72

PI intensity

[154]

25,300

30,700

25,900

1-5

RPMI for BxPC-3; DMEM
for Panc-1 & MiaPaCa-2

72

MTT

[155]

80

225

733

4

RPMI for all but Panc-1

48

PI intensity

[156]

RPMI for BxPC-3; DMEM
72
Alamar Blue Present study
for Panc-1 & MiaPaCa-2
Note: Grayed rows represent studies with experimental conditions and results most similar to the present study (also
grayed)
12.6

28.2

1.9

4
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Chapter 4 Supplemental Information

A

B

C

D

Figure S 1 Analysis in Harmony software of high-content assay
(A) The first step in the analysis was to count the total number of cells in the image. This was done by adding the
two channels which represented stained nuclei together (Hoechst 33342 and Edu) and detected all of the nuclei (B)
The invasion analysis involved creating a “sphere region” by blurring and thresholding the Mitotracker channel,
counting the nuclei within this region, and subtracting the number of cells within the sphere from the total number of
cells to quantify the number of invading cells. (B) Proliferative capacity was quantified by simply counting all of the
Edu-stained nuclei and dividing by the total number of nuclei. (D) Metabolic activity was quantified by thresholding
the raw Mitotracker channel to obtain a “metabolic region” and summing the intensity of the Mitotracker signal
within that region.
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